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1 Introduction 
 
The purpose of cancer research is mainly to improve knowledge about cancer. This way 
it is able to find out ways in preventing the occurrence of different cancers. Additionally, 
scientific research can improve and help to find new ways to diagnose and treat cancer 
more effectively. When it is able to discover improved ways to fight back cancer, there is 
a higher possibility to help people understand cancer and its origins better. Through open 
and linked global connections, we can as a society accomplish great actions towards the 
fight against cancer. (Cancer Research UK 2009 – 2014.) 
 
This thesis is strongly linked to the research of gastrointestinal stromal tumours ergo 
GISTs and its origins. In this particular research study, the meaning of MYB gene ex-
pression in GIST cancer cell lines was studied. Additionally, the basic function of protein 
production and ways to interfere this event, were examined during the study. Preliminary 
results of Dr. Sihto indicated that MYB gene might be controlling transcription of other 
genes which are known to be associated with GIST tumorigenesis (Sihto 2016). The 
most known gene that causes GIST is so called KIT gene and about 85 – 95% of this 
kind of tumours arise from the mutation in the KIT gene (Sihto 2016).  
 
The main purpose was to find ways to help preventing the formation of GIST cancer cells 
and understand more about how this particular tumour is shaped in the intestines. Fur-
thermore, this study might work as a foundation in helping to find out more about genetics 
behind tumour formation, especially concerning the role of MYB gene in GISTs. The aim 
of this study was to answer if the GIST cells express MYB gene and if imatinib or MYB 
specific siRNA reduce the protein or RNA signal of MYB in GIST cells.  
 
Research questions for this thesis were: 
1. Do GIST cancer cells express MYB gene? 
2. Does imatinib or MYB siRNA reduce the protein or RNA signal of MYB gene in 
GIST cancer cells? 
 
By using cell culture, the amount of the used GIST cancer cells was multiplied. The MYB 
gene expression was detected by using western blotting. With western blotting it was 
possible to reveal if cells produce protein that is coded by the MYB gene. This protein 
production was reduced by blocking transcription of the messenger RNA of MYB with 
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imatinib or MYB siRNA. When the amount of studied mRNA decreases, one can assume 
that the amount of protein decreases in the same proportion. When the production of 
abnormal MYB controlled protein level decreases, the effects of this decreasing in cell 
apoptosis or in cell proliferation in GIST cancer cells could be seen.  
 
This study was conducted to the research group of Heikki Joensuu, University of Hel-
sinki. For the research team, the purpose of this study was to gain more knowledge of 
MYB gene function. Research group of Heikki Joensuu had already supporting evidence 
from RNA sequencing results concerning this thesis and these results were the founda-
tion behind the thesis (Sihto 2016). Protein production of MYB in GIST cells was provi-
sionally discovered by western blotting. Moreover, RNA sequencing results had shown 
that the amount of MYB mRNA decreases when for example imatinib is added to the cell 
culture. To verify these results western blotting was repeated with imatinib treated cells 
and with MYB siRNA transfected cells. The results gained from the study will hopefully 
improve research team’s purpose of resolving the origins of GIST. 
 
The thesis consist of background about GIST and MYB, introduction to used laboratory 
materials and methods, analysing and reporting gained results, discussion with conclu-
sion and possible follow-up actions towards MYB research in GISTs. Additionally, there 
are six appendices related to this thesis. Information of this thesis can be used to study 
more about MYB gene expression in the further research of GIST.  
2 Background 
 
The most recognised ability of cancer cells is their way of sustaining unlimited prolifera-
tion. Normally tissues control their cell production and are able to release growth-pro-
moting signals that can guide the cell’s growth and division cycle. This release and con-
trol can help in maintaining homeostasis, keeping normal structure and controlling func-
tion of the cell. Cancer cells disturb these signals and this way ‘determine’ their own 
destinies. This chronic proliferation can be sustained in multiple ways. Cells can produce 
growth factor signals, they can send signals to stimulate normal tissues, and they can 
increase the levels of receptor proteins in the cancer cell surface and become hyper 
responsive towards growth factors. (Hanahan – Weinberg 2011.) 
 
Normal cells use negative-feedback to control their homeostatic balance. Damages in 
negative-feedback systems are able to enhance proliferative signalling for example in 
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cancer cells. Increasing expression of oncogenes and their protein production signals, 
on the other hand, can effect directly on elevated cancer cell proliferation and in that way 
to tumour growth. Additionally, cancer cells have to come up with programs that nega-
tively monitor cell proliferation. These actions are partially dependant on the cells disap-
peared action of tumour suppressor genes. Above all cancer cells need nutrients and 
oxygen and a way to lose metabolic wastes that angiogenesis provides in the form of 
tumour-associated neovasculature. (Hanahan – Weinberg 2011.) 
 
2.1 GIST 
 
GISTs are gastrointestinal mesenchymal tumours that generally embody CD117 (KIT) 
proto-oncogene protein. GIST tumours are just from 1 to 3 % of all of the GI tumours, 
but it is the most common soft tissue sarcoma of the gastro intestines. It is believed that 
GIST tumours originate from precursor cells of the interstitial cells of Cajal, which are in 
control of spontaneous abdominal peristaltic movements. Usually, the treatment of GIST, 
includes the removal of the tumour in 50% to 60% of cases. Additionally, imatinib can be 
used in metastatic GISTs or in GISTs that have a high risk of progression. (Lääkärin 
käsikirja 2014; Sihto 2016.)  
 
2.1.1 GIST diagnosis 
 
Generally GISTs are caused by activating mutations in the KIT or PDGFRA (Platelet 
Derived Growth Factor Receptor Alpha) genes. These tumours are normally found in 
stomach (60 %), small intestine, jejunum and ileum (30 %), duodenum (5 %), rectum (2–
3 %) and from colon (1–2 %). GISTs consist of a group of neoplasms with various mor-
phology, behaviour and genetic features. On histopathologic view, GISTs are epithelioid-
, spindle-, or mixed-cell tumours. These tumours can be categorised as malignant, bor-
derline or benign depending on its size, invasion to nearby tissues and mitotic index. 
(Poveda et al. 2013.) 
 
The diagnosis of these tumours mostly relies on its histopathological features and on the 
immunohistochemical phenotype. Anoctamin-1 (ANO1/DOG1) is known marker for 
GISTs and is used in differential diagnosis of GIST. Moreover, determination of KIT and 
PDGFRA mutations, are connected to GIST diagnostics. These mutations are helpful to 
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confirm diagnose in uncertain cases. The mutations can also help determine the re-
sponse of imatinib in tumours. (Gong – Li – Zhao – Zhao – Zhang 2009; Sihto 2016.) 
 
Mostly GISTs occur in humans at the age of 60. Additionally, GISTs usually encode mu-
tated tyrosine kinase receptors that are the most common therapeutic targets of tyrosine 
kinase inhibitors such as imatinib and sunitib. Wild-type versions of GISTs occur 85% – 
90% on children and only 10% – 15% on adults. These wild-type GISTs are character-
ized with the lack of KIT or PDGFRA mutation. For these GISTs, imatinib and sunitib 
have been noticed to be less effective choice of treatment. Both KIT and PDGFRA en-
code similar tyrosine kinase receptors structurally and in GISTs mutations at those genes 
result in abnormal activity of proteins. These proteins have constitutive increased onco-
genic signalling when they have mutated absence of their important ligands. Altered and 
uncontrolled kinase activity causes alternations to protein translation, cell cycle, apopto-
sis and cell metabolism. Metastases of GISTs are rare and are mostly seen only in the 
late-stage disease or in pediatric GISTs as lymph node metastases. (Foo – Liegl-
Atzwanger – Lazart 2012.) 
 
2.1.2 GIST mutations in research 
 
Ostrowski et al. studied molecular characteristics of tyrosine kinase receptors in family 
three that are connected with known GIST mutations in KIT and PDGFRA. Both muta-
tions are thought to promote early oncogenic events in similar pathways. Purified RNA 
from the GISTs and sequencing of mRNA was used to clarify these KIT and PDGFRA 
mutations. Most of the tumours possessed either or both of these mutations. Gene ex-
pression altered between two groups of GISTs at some levels for example considering 
angiogenesis. Their study found new molecular elements that might be involved in re-
ceptor-dependent GIST evolution and also backed up previously known information 
about GIST receptors. These molecular elements might be good therapeutic targets and 
markers of KIT mutation status. (Ostrowski et al. 2009.) 
 
In Heinrich et al. research study in year 2006 these oncogenic mutation spots KIT and 
PDGFRA were noticed to develop new imatinib resistant secondary mutations. In the 
study of 147 patients with advanced GISTs, effects of imatinib was studied in a clinical 
environment. Samples of GISTs were from pretreatment or from imatinib-resistant tu-
mours. Samples were biochemically analysed to identify molecular imatinib resistance 
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and to identify imatinib resistant secondary kinase mutations of KIT or PDGFRA. Sam-
ples were also profiled for imatinib sensitivity. Results showed that imatinib-resistant tu-
mours had similar or greater levels of KIT with untreated GISTs. Secondary kinase mu-
tations seemed to be rare in primary resistance GISTs but often found in secondary re-
sistance GISTs. In Heinrich et al. study secondary kinase mutations were linked to re-
duced imatinib sensitivity compared with more characteristic KIT exon 11 mutations. 
Imatinib-resistant GISTs seem to remain dependent on KIT kinase activity in activation 
of downstream signalling pathways. Heinrich et al. proved that biochemical molecular 
mechanisms are in charge of primary and secondary imatinib resistance in GISTs. (Hein-
rich et al. 2006.) 
 
Furthermore, primary and secondary kinase genotypes were studied in another Heinrich 
et al. study in the year 2008. Impact of genotypes were studied with the activity of drug 
sunitib due to imatinib-resistance. The study was conducted with 97 patients with meta-
static, imatinib-resistant or imatinib-intolerant GISTs. Mutational KIT or PDGFRA status 
was determined of 78 patients with the use of tumour specimens that were obtained 
before and after prior imatinib therapy. Sunitib and imatinib sensitivity were biochemically 
profiled from kinase mutants. Clinical usefulness with the use of sunitib was seen in the 
three most common primary genotypes of GIST: KIT exon 9 in 58%, KIT exon 11 in 34% 
and a wild-type KIT or PDGFRA in 56%. The progression-free survival and overall sur-
vival rate were longer for patients with primary mutation in KIT exon 9 or with wild-type 
mutations than patients with mutation in KIT exon 11. Additionally, secondary mutations 
in KIT exon 13 or 14 had longer survival rates than secondary mutations in KIT exon 17 
or 18. Sunitib’s clinical effect after failure in imatinib treatment is influenced by both pri-
mary and secondary mutations which correlates to the need of optimization of the treat-
ment for GIST patients. (Heinrich et al. 2008.) 
 
Genetically downstream targets for KIT were studied in pediatric GISTs by Agaram et al. 
in the year 2008. Pediatric GISTs are quite rare and occur primarily in females. Typically 
these GISTs lack the usual mutations in KIT and PDGFRA genes, but typically the KIT 
oncoprotein is often overexpressed in pediatric GISTs. This reason, KIT downstream 
targets and alternations in KIT or PDGFRA gene copy numbers were investigated. Over-
all, 17 pediatric GISTs were studied for KIT or PDGFRA genotype and biochemical acti-
vation in KIT downstream targets. Pediatric GISTs proved to have a distinct transcrip-
tional signature with overexpression of KIT downstream targets PLAG1, FGF4, NELL1, 
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IGF1R and BAALC. These signatures suggest that pediatric GISTS have different bio-
logical features than what wild-type adult GISTs have. (Agaram et al. 2008.) 
 
2.2 Proto-oncogene MYB 
 
MYB is a proto-oncogene that is located on chromosome 6q in human genome. Its main 
function is to encode a 72 kDa nuclear binding transcription factor. Transcription factor 
in question is identified to be a sequence-specific DNA-binding transcriptional regulator 
protein in human cells. There are three main functional areas; amino terminus as a DNA 
binding domain, mid portion as a transcriptional trans-activating domain and also car-
boxyl terminus as a negative regulator in this transcription factor. MYB is especially found 
in hematopoietic cells and MYB expression is particularly high in immature hematopoietic 
cells. Recently MYB has been found also from non-hematopoietic cells and from cancer 
cells involving lung, breast, colon carcinoma and melanoma. (Kim et al. 2008.) 
 
2.2.1 Function of MYB gene 
 
The family of MYB genes consist of three different types of MYB, which are named A, B 
and c-Myb. All of these genes encode proteins that are involved in transcription. This 
study focuses on the gene c-Myb and that particular gene is called in this thesis the MYB 
gene. The transactivation of different MYBs varies highly on different cell types and in 
promoter contexts. This variability between different MYBs suggests that there are also 
dependence with MYBs and other cell type specific co-factors for example interaction 
with other transcription factors. Gene expression of these genes is noticed to be cell 
cycle-regulated. If this expression is inhibited with anti-sense oligonucleotides, it may 
effect on cell-cycle progression, cell differentiation and cell division. (Oh – Reddy 1999.) 
 
V-myb is a transforming homolog oncogene of MYB that is connected to avian myelo-
blastosis virus (AMV) and to avian leukaemia virus E26. These viruses are strongly con-
nected to leukaemia. The so called v-myb genes are able to transform haematopoietic 
cells in tissue cultures and causes leukaemia in animals. Because the MYB protein is 
known to be a DNA-binding transcription factor, its oncogenic activity might be linked to 
its capacity to monitor specific target genes that impact cell reproduction or tumorigene-
sis. (Kim et al. 2008; Quintana et al. 2011.) 
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2.2.2 Role of MYB in cancer 
 
Bell et al. studied recurring of MYB gene translocation of t(6;9)(q22–23;p23–24) in ade-
noid cystic carcinoma (AdCC) of salivary glands. High expression of transcriptional factor 
MYB was found in many AdCCs. Bell et al. investigated the biological and predictive 
significance of the increased levels of MYB and its known downstream targets (c-kit, cox-
2 and bcl-2). 156 AdCCs samples protein expression of these genes were analysed by 
immunohistochemical methods. Results showed that 55% of the studied AdCC samples 
had increased MYB expression. Moreover, the combination of MYB+/c-kit+/cox-2+ had 
better survival rate than combination of MYB-/c-kit+/cox-2+ AdCCs. Results from Bell et 
al. study indicate that MYB might serve as a target for the management of AdCC. (Bell 
et al. 2011.) 
 
In research study of West et al. MYB gene was additionally examined in adenoid cystic 
carcinoma. They also discovered that translocation t(6;9)(q22-23;p23-24) was con-
nected to multiple cases of AdCC. Moreover, the fusion between transcription encoding 
MYB gene and NFIB transcription factor in 6 out of 11 occasions of AdCC was discov-
ered. At that time only a potential pathogenic translocation suggested it to be a useful 
diagnostic advantage for differentiation of AdCC. In the study of West et al. MYB trans-
location was searched by increased levels of MYB expression. MYB translocation was 
discovered from one-half of the AdCC cases (49 %), but from the other salivary gland 
tumours there were no MYB translocation to be found. All in all, 65 % AdCCs have an 
unusual MYB FISH pattern, which indicates MYB translocation. (West et al. 2011.) 
 
Quintana et al. studied the role of MYB gene in breast cancer and MYB connection to 
estrogen levels and estrogen response in breast cancer cells. Their idea was that ex-
pression of MYB gene is associated with the estrogen receptors (ERs) in breast tumours. 
The MYB gene reacts to the activation of ERs in certain known breast cancer cell lines 
such as MCF-7. MYB transcription factor was thought to be connected in the regulation 
of many different gene expressions that are important in breast cancer evolution and 
progression. Thus, when MYB gene is activated and starts to produce transcription fac-
tor, other genes react to this transcription factor and start for example producing breast 
cells in an uncontrolled way. Linkage to ERs in breast cancer may also indicate that MYB 
transcription factor is regulated mainly by different protein to protein interactions. These 
Interactions may help to guide MYB transcription factor to different targets in multiple 
tissues. (Quintana et al. 2011.) 
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Furthermore, MYB expression was studied in connection to vav1 signal transducer pro-
tein positive lung cancers in Ilan – Katzav research study in the year 2012. They demon-
strated how the vav1 promoter affects its transcription in different histological origins be-
cause of mutations in its transcription factor binding sites. Exhaustion of MYB with siRNA 
was seen as a reduction in vav1 expression in lung cancer cells. Additionally, co-trans-
fection of MYB activated transcription of vav1 promoter decreased vav1 expression. 
These results indicated that MYB is involved in lung cancer through vav1 expression. 
(Ilan – Katzav 2012.) 
 
In hematopoietic cancers – such as T-cell acute lymphoblastic leukaemia aka T-ALL – 
MYB expression can work with so called super-enhancers that effect to known onco-
genes for example in T-ALL TAL1 oncogene. This was discovered in research study of 
Mansour et al. in the year 2014. MYB transcription factor was investigated to effect an 
upstream super-enhancer of TAL1 oncogene. MYB binds itself upstream of TAL1 and 
recruits its binding partner CBP among other components of leukaemogenic transcrip-
tional complexes. In Mansour et al. study, they reduced the activity of the mutant report-
ers after MYB knockdown, which indicated that the enhancer activity passed by the mu-
tations was indeed meditated by MYB. In T-ALL samples and cells mutations that intro-
duce MYB binding sites were at a hotspot 7.5 kb upstream from TAL1. This binding of 
MYB creates a super-enhancer that drives monoallelic overexpression on TAL1 onco-
gene. In this study Mansour et al. used new MYB antibodies in generating maps of ge-
nome-wind binding of MYB in Jurkat cells. TAL1 enhancer’s mutation site analysis in 
Jurkat cells pointed out the precise alignment of MYB binding and binding of all the mem-
bers of TAL1 complex. siRNA knockdown of MYB resulted exhaustion of TAL1 expres-
sion in both used cell lines (Jurkat and MOLT-3 cells). (Mansour et al. 2014.) 
 
Generally, there is only little known about MYB in tumorigenesis in human cells. More 
studies and advanced techniques may be required to resolve the mysteries of MYB. 
More results may help to understand which kind of signals and regulators are important 
in the role of controlling the activity of MYB transcription factor. However, it is not yet 
absolutely clear if the MYB transcription factor regulate genes that are involved in tumour 
growth. (Quintana et al. 2011.) 
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2.3 Imatinib and siRNA 
 
Imatinib is a drug that is used in drug therapy of GISTs, chronic myeloid leukaemia (CML) 
– that is Philadelphia-chromosome positive – and acute lymphoblastic leukaemia et 
cetera. Imatinib is a tyrosine kinase inhibitor that works by blocking the function of tyro-
sine kinases with abnormal enzymatic activity. Target proteins for imatinib are, among 
other oncoproteins, KIT, PDGFRA and BCR-ABL (connected with CML). These targets 
can be in charge of giving cancer cells signals to multiply without control. Imatinib helps 
preventing the uncontrolled growth in cancer cells. (Imatinib (Glivek) 2015; Sihto 2016; 
Lee – Wang 2009.) 
 
Imatinib is characterized as an effective drug in cancer treatments and also in small-
molecular targeted therapies. Nevertheless, it possess some mild adverse effects such 
as muscle cramps, edema, diarrhea and bone-marrow toxicity. These effects might 
sometimes cause patients to discontinue imatinib treatment. Despite of adverse effects, 
imatinib versatility on multiple diseases makes it a fine treatment option for cancers. (Lee 
– Wang 2009.) 
 
siRNA is a small interfering RNA that interferes expression of protein coding genes. 
siRNA is a synthetic duplex RNA designed to attach identical corresponding mRNA in 
sequence to undermine its function. When attached, siRNAs can block the protein pro-
duction. siRNAs can also knockdown gene expression by causing promoter genes meth-
ylation and chromatin condensation. Their ability to induce gene knockdown is limited to 
cells that are receptive to transfection of synthetic oligonucleotides. (Ross –Carlson – 
Brock 2007; Dharmacon 2016.) 
3 Materials and methods 
 
GIST cell lines for this study were kindly provided by Jonathan Fletcher MD from Boston, 
Massachusetts, United States of America. Cells were separated from human GISTs and 
they were molecularly characterized as GIST cells. GIST882 cell line was established 
from a patient with untreated metastatic GIST. This cell line expresses’ a homozygous 
missense mutation in KIT exon 13. This mutation was resulted by a single amino acid 
substitution (K642E), in the proximal area of the split tyrosine kinase domain. In addition, 
GIST882 contains monosomy of chromosomes 14 and 22. Other cell line used, GIST48, 
was established from progressed GIST after clinical response to the given treatment 
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(imatinib therapy). Cell line 48 contains primary in KIT exon 11 missense mutation 
(V560D) and secondary missense mutation (D820A) in KIT exon 17 (kinase activation 
loop). (Bauer – Duensing – Demetri – Fletcher 2007; Tuveson et al. 2001; Bauer – Yu – 
Demetri – Fletcher 2006.) 
 
Cell lines were cultured to the optimal stage of growth and after that protein levels of 
cells were studied by using SDS-PAGE western blotting. In addition, to gain more 
knowledge, RNA level of MYB was studied by performing RNA isolation and qPCR on 
GIST cell lines. 
 
3.1 Cell culture 
 
In cell culture, cells are grown in an optimal artificial environment. Cells are removed 
from an animal or humans and they can be removed from tissues directly. Before cultur-
ing, cells can be manipulated by enzymatic or mechanical means or they can be sepa-
rated from a cell line that has already been established. The condition to grow cells vary 
depending on the cell type in use. The artificial environment to grow cells though contains 
primarily the following aspects: 
 
- A substrate that includes essential nutrients (for example amino acids and car-
bohydrates) 
- Growth factors 
- Gases (oxygen and carbon dioxide) 
- Hormones 
- Regulated environment (pH, osmotic pressure, temperature) 
 
(Thermo Fisher Scientific 2016.) 
 
To culture cells in laboratory environment, the laboratory must have certain aspects. La-
boratory is recommended to be dust free and have no through traffic that can have a 
harmful effect to the cells. Laminar flow hoods allow these aspects to be fulfilled. Laminar 
flow hoods provide also an aseptic area for working with tissues. The laboratory should 
also be separated from the preparation area, wash-up and sterilization places, while still 
being close to each other on primary cell cultures. (Freshney 2010: 25, 37.) 
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An artificial substrate is a base where cultured cells can grow as monolayers or as a 
suspension. That is why the substrate must allow cell adhesions, which allows cells to 
grow and spread throughout the surface. The most commonly used substrate materials 
are disposable plastic and glass. These materials can be pre-treated with for example 
nutrients that improve cell attachment and growth. (Freshney 2010: 89–90.) 
 
Growth factors in serum stimulate cell proliferation, especially those factors that are 
platelet-derived (PDGF – platelet-derived growth factor). PDGF is known to stimulate 
growth particularly in glia cells and also in fibroblasts. Other growth factors such as fibro-
blast growth factors and epidermal growth factors are to be considered in cell cultures. 
Many of these factors are available for buying as recombinant proteins. Hormones that 
have a mitogenic feature, like insulin, growth hormone and hydrocortisone, are used in 
cell cultures. Insulin improves the up taking of glucose and amino acids. Hydrocortisone 
for its part, can promote cell to cell attachments. (Freshney 2010: 111.) 
 
As for the controlled and stable environment of the cell culture, cell type specification 
define the used physical aspects. Commonly most cells are accustomed to grow well at 
pH 7.4. Carbon dioxide helps lowering the pH by dissolving into bicarbonates. Addition-
ally, oxygen is required to maintain the cell respiration. Although, it is important to stable 
the oxygen level to the stage where it helps respiration but does not release toxins to the 
culture. The variation in osmolality is widely tolerated among different cells, but recom-
mended osmolality in culture is between 260 mOsm/kg and 320 mOsm/kg. As for tem-
perature, it is recommended to resemble the original source of the cells (growing human 
cells temperature is optimal in 37 °C). (Freshney 2010: 99–106.) 
 
3.2 SDS-PAGE 
 
In SDS-PAGE, proteins are examined in their denatured state. The SDS-PAGE gel itself 
contains SDS (Sodium dodecyl sulfate) and the PAGE gel (Polyacrylamide gel) can be 
used with SDS in the running buffer (PubChem 2005; BioRad 2016). Denatured state 
enables the estimation of protein individual molecular weight and can be an additional 
property to separate proteins from each other. The SDS itself is an anionic detergent that 
has an ability to unfold protein structures and provides them extra negative charge by 
binding into the proteins in high temperature. The number of negative charges and the 
amount of attached SDS molecules is related to the length of the studied polypeptide 
chain. (Hegyi et al. 2013.) 
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The charge-to-mass-ratio and the shape of the protein will become approximately iden-
tical to different proteins upon SDS-treatment. Hence, the used SDS gel is able to sep-
arate individual polypeptide chains merely by their size. This way SDS-PAGE basically 
separates proteins by their molecular mass (size is a linear function to mass). Proteins 
that have a known molecular mass can be used to form a calibration curve which helps 
to estimate the unknown molecular masses of other proteins. (Hegyi et al. 2013.) 
 
3.3 Western blotting 
 
Western blotting is a technique that is used to separate wanted proteins based on a mass 
of proteins. The technique is based on transferring proteins from the separating gel onto 
a supporting matrix. This blotting style allows for fast staining and for destaining protocols 
of the separation of proteins. In western blotting, protein samples are separated in a gel 
through gel electrophoresis and after that electroblotted onto a support matrix. Once this 
is done, proteins can be labelled with anything that is able to selectively bind into pep-
tides to identify the presence or absence of specific spots. This detection of proteins can 
be reached via an enzyme fit for use with a changing ways of colorimetric, chemilumi-
nescent or fluorescent substrates. (Walker – Rapley 2005: 43.) 
 
After the gel electrophoresis, protein transfer from the gel is accomplished by using an 
electric potential through the gel and the membrane. The applied membrane can be ni-
trocellulose, nylon or polyvinylidene difluoride (PVDF) base. This membrane provides 
much more stable environment than the gel, making later manipulations considerably 
easier. Electroblotting is the most common western blotting technique, but also tech-
niques such as capillary blotting can be used. (Walker – Rapley 2005: 43–44.) 
 
PVDF membrane tides proteins to itself via dipole and hydrophobic interactions. The 
PVDF membrane does not let proteins through and is less fragile than for example nitro-
cellulose (PVDF Membranes for Western Blotting. 2015). For electroblotting the proteins 
from gel to the membrane, a so called sandwich is built. For the ‘sandwich’, gel and the 
membrane are placed between filter papers and foam pads. Pads and paper are so light 
and spongy materials that electric current can easily transfer through them. They also 
protect the PVDF membrane and the SDS-PAGE gel. Filter papers and foam pads are 
damp in transfer buffer and the PVDF membrane is activated before use in methanol for 
one minute. (Western Blot Transfer Methods. 2015.) 
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Following transfer to the membrane, finding of the target proteins is commonly accom-
plished by using specific antibodies. The implantation of these specific antibodies to their 
target proteins can be performed by using methods that are based on indirect or direct 
immunoassays. Immunoassay methods include the using of multiple labels that are con-
jugated to an antibody. In direct method, the signal of these labels is noticed directly 
when the antibody attaches itself to the protein that is looked for. When in indirect immu-
noassay methods, the signal can be achieved by using enzymes that can act on partic-
ular substrates. (Walker – Rapley 2005: 46.) 
 
3.4 RNA isolation 
 
Generally RNA is separated from cells to transform it into cDNA. RNA is degraded quite 
easily especially when enzymes called RNases are present. RNases are enzymes that 
break RNA into pieces in cells so that the parts of RNA can be reused to build new RNAs. 
The used materials should be handled with reagents, such as guanide thiocynate, that 
inactivates RNases. Overall, RNA should be handled on ice bath to prevent any extra 
biochemical reactions. RNA can be isolated for example from tissues, cultured cells, 
plants or from bacterial cells. (Suominen – Pärssinen – Haajanen – Pelkonen 2013: 108–
109.) 
 
In silica column method of RNA isolation RNA is attached to silica membrane in high salt 
concentration. RNases can be inactivated by specific lysis buffer that contains for exam-
ple chaotropic ions. Buffer also creates an atmosphere where RNA can bind to silica 
membrane. Binding of DNA is prohibited by rDNase that binds to the silica membrane 
instead of DNA molecules. Washing the membrane with high concentrated liquid re-
moves unwanted particles such as salts, metabolites and other macromolecular parti-
cles, but keeps the RNA attached to the column. Pure RNA is removed from the silica 
membrane with low salt concentration RNase free water. (RNA isolation 2014.) 
 
After the isolation of RNA from cells or tissues, the purity of the gained product should 
be measured. Purity measurement can tell the amount of isolated RNA and possibility of 
contaminations (for example proteins) in the eluted sample. The most common meas-
urement technique is based on nucleic acids ability to absorb in 260 nanometres. Purity 
is calculated by preparing the gained results on 280 nm wavelength. Pure RNA the cal-
culated purity is 2.0 absorption in 260 nm wavelength. (Suominen et al. 2013: 110–111.)  
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3.5 qPCR 
 
PCR ergo polymerase chain reaction is used to multiply known DNA regions. The 
method is based on DNA polymerase enzyme that can multiply DNA sections on high 
temperature and on two specific primers that define the multiplied DNA section. In real-
time PCR the creation of wanted nucleic acid can be monitored live while the reaction 
proceeds. Real-time PCR is based on fluorogenic tracer. Tracer’s fluorogenic signal mul-
tiplies when attached to the finishing two strand PCR product. To get quantitatively meas-
ured amount of PCR product, this gained fluorogenic signals is used to calculate the 
amount of wanted product in the used sample. Real-Time quantitative PCR ergo qPCR 
the gained PCR product can be quantified by using relative or absolute methods. In the 
more common relative quantitation the amount of the target gene is compared to the 
amount of reference gene. (Suominen et al. 2013: 153–154, 166–170.)  
 
For real-time PCR, TaqMan method focuses on fluorogenical features of the used probe. 
This probe contains a fluorescent reporter dye, which is attached to its 5’ end, and a 
quencher dye that is linked to its 3’ end. When present of the target nucleic acid se-
quence, TaqMan probe anneals downstream from primer site and is so called cleaved 
by the 5’ nuclease activity of polymerase enzyme in the extension phase of the real-time 
PCR. While the probe is being intact in the sequence chain, fluorescence resonance 
energy transfer particle appears and the fluorogenic emission of the 5’ reporter dye is 
reduced by the quenching dye. Cleavage of the used probe by polymerase enzyme Taq 
during the PCR divides the two dyes of each other. This action strengthens the fluores-
cence from the reporter dye. Moreover, cleavage detaches the probe from the target 
sequence, letting the primer extension to carry on to the end of the template strand. This 
way it does not interfere with the exponential accumulation of the wanted PCR product. 
In each cycle, additional reporter dye molecules can be cleaved from their probe, which 
leads to increased fluorescence intensity amount to the proportion of amplicon produced. 
This increased fluorescence emission can be detected by special modified thermocycler 
computer software. (Arya et al. 2005.) 
 
Computer calculates the fluorescence emission by using relative quantification. In rela-
tive quantification mRNA levels of gene samples are determined and expressed rela-
tively to the levels of calculated internal RNA control. This used control reference gene 
can be so called housekeeping gene which can be co-amplified in the same tube or can 
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be amplified in a separate tube. Relative quantification, therefore, does not need any 
standards with known concentrations and the reference can be any transcript that has a 
known sequence. Quantification of this kind is merely based on the expression levels of 
a target gene compared to a reference gene. Calculations can be based for example on 
the comparison of the crossing points and threshold values at a constant level of fluo-
rescence. (Quantification strategies in real-time RT-PCR n.d.) 
 
The used template for PCR is DNA. When multiplying RNA, it must first be transferred 
into DNA. In reverse transcription PCR, RNA is transferred with reverse transcriptase 
into complementary DNA ergo cDNA. This can be done in multiple ways but the results 
in all of them is two stranded cDNA that is formed of using one stranded RNA as a base. 
(Suominen et al. 2013: 170.) 
 
3.6 Protocol 
 
The idea behind this study was to demonstrate MYB expressions possible diminish on 
protein level by effect of imatinib or MYB specific siRNA. Also RNA level was studied. 
Used GIST cell lines, line 48 and line 882, were grown in cell culture as monolayers in 
plastic flasks at +37 °C and in 5% carbon dioxide. Reagent and materials used in this 
study are demonstrated in Appendix 1.  
 
Line 48 was already being maintained in T75 flask by the research group. Line 882 cells 
were picked up from -150 °C freezer and removed from there to grow in T75 sized flask 
(protocol demonstrated in Appendix 2). Cells were maintained before dividing them into 
T25 sized flasks by changing their medium regularly and dividing them if needed (con-
fluence being round 70% to 80%). Protocols demonstrated in Appendix 2. Confluence is 
the amount that cells cover the base of the bottle. As a cell growth medium, RPMI-me-
dium base was used. To medium base inactivated fetal bovine serum, penicillin and 
streptomycin glutamine were added. In case of siRNA transfection, cells were divided 
from T75 flasks to 6-well microtiter plate or into T25 flasks.  
 
3.6.1 Imatinib treatment 
 
Both cell lines were divided into smaller T25 flasks at relation 1:4 (divided from 1ml cell 
suspension in other words 250 µl was added to each bottle from 1 ml). Cells were studied 
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in two different periods of time: after 24 hours and after 48 hours from the adding of the 
drug to the cell culture. For comparability and reliability, two flasks for each cell line con-
tained control cells (no drug added) and two flasks contained 0,5 µM imatinib (diluted to 
the used RPMI medium). For 24 hour analysis, there were four flasks for each cell line, 
and for 48 hour analysis, there were also four bottles for each cell line. Altogether, sixteen 
T25 flasks were used (presented in Picture 1.). 
 
 
Picture 1.    Imatinib treated cell line  
Before dividing cells optimal confluence should be from around 70% to 80% so that cells 
are in an optimal growing stage. Used cell lines were about that. Line 882 was closer to 
90%. Each T25 flask contained 5 ml of medium and 250 µl of cell suspension. Cell sus-
pension was made to the medium in use (1 ml of medium). Cells were cultured for 24h 
or 48h with or without the imatinib drug. Before the medium was changed (with or without 
the drug) confluence was in 48 about 50% and in 882 about 90% (line 48 cells were 
observed to grow much slower than the line 882).  
 
Cell lysis was performed after the 24 hour mark and after the 48 hour mark for the cells. 
RIPA buffer with added phosphatase inhibitor and protease inhibitor was used as a lysis 
buffer. Detergents in RIPA buffer dissolve cell membranes and that way break the cell 
Cell lysis after 24 
hours 
Cell lysis after 
48 hours 
Controls imatinib 
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structures (Overview of Cell Lysis and Protein Extraction. 2015). Added inhibitors pre-
vent different cell enzymes (such as proteases) from working and specific detergents are 
used if for example only the nucleus envelope needs to be broken (Overview of Cell 
Lysis and Protein Extraction. 2015). The amount of lysis buffer was decided by the con-
fluence of the cells at lysis moment (amounts of lysis buffer used in Appendix 5). Lysis 
was performed on ice bath with +4 °C RIPA buffer to prevent denaturation of proteins 
and also preventing any extra biochemical reactions in cells. Cells were detached from 
the T25 flasks with cell scraper and moved to 1,5 ml Eppendorf tubes. After lysis, cells 
were furthermore scattered with sonic soniprep 150 machine. The machine scattered the 
cells by using high pitch sound that broke cells and separated the proteins out to be used 
and measured. Between cell scattering and before making western samples cells were 
stored at -70 °C freezer. Working protocol for cell culture is demonstrated more thor-
oughly in Appendix 2. 
 
Now ready to use samples of GIST cells, the protein level of the samples was measured. 
Protein measurement was conducted with Pierce™ BCA Protein Assay Kit by Thermo 
Fisher Scientific with colorimetric absorbance detection. For BCA aka bicinchoninic 
acid assay measuring, samples were diluted to RIPA buffer (882 1:10 and 48 1:2). Dilu-
tion was determined by the amount of cells there were before lysis in cell culture. Meas-
ured samples were compared to standard sample dilution series for determining the total 
amount of protein in the actual samples. The standard sample dilution series was pro-
vided in the assay kit and diluted according to the given instructions of the kit. For meas-
uring, 96-well microtiter plate was used and from each Eppendorf tube duplications were 
made. Ten microliters of wanted sample and 200 µl of BCA reagent was used. After 
adding the reagent, plate was left to +37 °C to incubate for half an hour. After incubation 
samples were measured. Because of pipetting errors of the first time around, samples 
were remeasured on the next day to get more reliable results. Final and used protein 
measurement are presented in Appendix 5. 
 
Using the absorbance, the amount of total protein level of the samples was able to be 
calculated. Using this information, it was able to determine the microliter amount in 25 
µg of proteins in each sample. Using that information it was able to dilute the samples to 
Laemmli and β-mercaptoethanol. The bromophenol blue in Laemmli buffer colours the 
samples with deep purple colour and β-mercaptoethanol denatures the proteins of the 
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sample by reducing disulphide bonds between peptides in protein structure (Sigma-Al-
drich 2016). Samples were diluted on ratio 1:1. After the preparation, samples were kept 
in a -70 °C freezer for 5 days. 
 
At the beginning of western blotting for imatinib treated cells, samples were melted on 
ice bath. This was important so the protein in the samples would not break before gel 
electrophoresis. Samples were loaded onto 10-well/ 50 µl per well SDS-PAGE gel. The 
map for the wells and loading of the samples is presented in Picture 2. Samples run in 
gel electrophoresis for one hour and fifteen minutes at 100V. After the run, the gels were 
prepared for the blotting part of western blotting. Proteins were electroblotted from the 
gels to the protein membrane PVDF according to western blot protocol (Appendix 3). 
The samples were left in transfer buffer over the night to electroblot in 0.15 A in +4 °C 
cold room.  
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Picture 2.    Sample map on SDS-PAGE gels  
On the second day of western blotting, ‘sandwich’ was opened and the membranes were 
soaked in Ponceau S solution for one minute. Ponceau S solution colours proteins so 
that the blotting is visible from the gels on to the membranes and can be immunologically 
detected. After the colouring, membranes were washed in washing buffer (TBS+tween) 
for one minute and then left for one hour in 5% milk for blocking of the protein action. Fat 
free milk and its albumin proteins attach to empty spots in the membrane preventing 
unspecific antibody attachments on to the membrane later on in the western blot protocol 
(Sihto 2016). This way the wanted specific protein has better chances to be visualised 
from the membrane. After the blocking, membranes were washed at 3 times for 5 
minutes per time. To the clean membranes antibody action was started to detect specific 
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MYB protein from the membranes. First, primary MYB antibody was added to the mem-
branes. Primary antibody clings onto protein by making protein-antibody complexes. Pri-
mary antibody was left over night to cling onto proteins at +4 °C cold room.  
 
After the primary antibody, the membranes were again washed for 3 times at 5 minutes 
per time. The secondary antibody (rabbit anti-mouse IgG) to enhance the signal of the 
formed protein-antibody complexes, was added on top of the membranes and left for 
one hour at room temperature. The secondary antibody was labelled with HRP aka 
horseradish peroxidase which substrate is chemiluminescent. This way secondary anti-
body enhances the chemiluminescent signal of primary MYB antibody. After the second-
ary antibody and new washings, chemiluminescent substrate for detecting the signal of 
complexes was added to the membranes for 5 minutes. Chemiluminescent signal was 
detected after light exposure by x-ray films and the magnitude of the reaction is directly 
correlated to the amount of protein in the sample. The working protocol is demonstrated 
more thoroughly in Appendix 3. 
 
Because the unique behaviour of the MYB protein, it had to be tested in different con-
centration of antibodies and in different light exposure times to detect the bands of the 
membranes. The result was eventually gained by using 1:3 femto chemiluminescent sub-
strate (Thermo Fisher Scientific – Supersignal West Femto Maximum Sensitivity Sub-
strate) and 2:3 pico chemiluminescent substrate (Thermo Fisher Scientific – Supersignal 
West Pico Chemiluminescent Substrate) mixture for five minutes per membrane. The 
exposure times varied from 30 seconds to 45 seconds. Also, 1:500 primary antibody and 
1:10 000 secondary antibody were used.  
 
3.6.2 siRNA transfection 
 
As mentioned previously, GIST cells for transfection of the siRNAs were first divided on 
6-well microtiter plate. Confluence was, before dividing the cells, in both cell lines round 
90 %. Cells were counted by using Bürker chamber and diluted in Trypan blue solution 
that stains cells. Four A-squares were counted and then the average of the cells in one 
square was used in calculating the total sum of cell in one milliliter suspension. 600 000 
cells was placed per well of 882 cells and 700 000 cells of 48 per well. All in all, one 6-
well plate was used per cell line. Media for the cells was specially made antibiotic-free, 
because of the toxicity of penicillin to cells and penicillin’s negative impact in transfection 
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effectiveness (Factors Influencing Transfection Efficiency. 2015). The 6-well plate is 
demonstrated in Picture 3. 
 
 
 
 
 
 
 
 
 
Picture 3.    6-well microtiter plate for siRNA transfection  
Transfection of the siRNAs for the cells was started with cell starvation. Starvation was 
performed by using Opti-MEM solution that lacked every substance for cells to grow and 
to use. Cells were left to starve for six hours and after that siRNAs were transfected. The 
starvation helps siRNAs to transfect, because after the starvation cells are more eager 
to phagocyte substances to themselves. Before the transfection, siRNAs were diluted to 
Opti-MEM solution and mixed with Lipofectamine that was also diluted to Opti-MEM so-
lution. Lipofectamine creates a vehicle for the cells to transfect more easily through cell 
membrane (How Cationic Lipid Mediated Transfection Works. 2015). For the transfec-
tion, Opti-MEM was removed and antibiotic free growth medium was placed to the 6-well 
plate. Medium worked as a transfection and growing base, when siRNAs were added to 
each well. In this study control siRNA (called scramble that is known transfect cells with-
out targeting genes and that way does not prevent any gene expression), MYB siRNA 
and KIT siRNA were used. Control and KIT siRNA were added to confirm the result from 
MYB siRNA. Protocol for transfection of the cells is demonstrated in Appendix 2. 
 
After 48 hours from the transfection, cells were removed from the 6-well plate by cell 
lysis into Eppendorf tubes and structures of the cells were broken by sonic soniprep 150 
machine as described above. The same BCA measuring and western blotting samples 
were made from siRNA cells as from imatinib treated cells. The western blotting protocol 
for siRNA did not vary much from the imatinib treated cells. For each cell line, own SDS-
PAGE gel was used and the same concentration on antibodies also. Unfortunately, 
siRNA transfection had to be repeated with T25 cultured flasks due to lack of cell material 
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from the 6-well plate. Working protocol for western blotting is demonstrated in Appendix 
3. 
 
3.6.3 RNA protocol 
 
To confirm the MYB expression on RNA level, RNA needed to be isolated from GIST cell 
lines 48 and 882. Also to confirm the effect of imatinib and siRNA in these cells, imatinib 
treatment and transfection of the siRNAs had to be performed. To get enough cells for 
the isolation, cells were divided to 24-well microtiter plate (demonstrated in Picture 4). 
Also, as for control, MDA-MB-361 breast cancer cell line was used. RNA was isolated 
by using the silica method of Machery-Nagel’s RNA isolation (RNA isolation 2014). The 
purity of the isolated RNA and the concentration of the RNA was measured with Thermo 
Scientific Nanodrop 2000 Spectrophotometer.  
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Picture 4.    Cell culture in 24-well microtiter plate for RNA isolation  
To carry out quantitative PCR, the isolated RNA had to be transferred into complemen-
tary DNA. Reverse transcriptase enzyme can translate RNA particles to double stranded 
DNA. The amount of the used template was determined by the amount of the pure RNA. 
For example, if there were under 10ng of RNA 15µl of template was used. The translation 
was carried out with Dyad Disciple by Thermal Cycler. The purity and concentrations of 
RNA are demonstrated in Appendix 5.  
22 
  
Program: 
- Incubation +25 for 5 min 
- Incubation +46 for 20min 
- Incubation +95 for 1min 
- Incubation +4  
- Ending 
 
Translated cDNA was then ready for PCR. For the PCR, a reaction mix or PCR mix was 
made. The mix included buffer, forward primer, reverse primer, probe and sterile water 
(demonstrated in Appendix 4). Different mixtures were made for MYB and for the used 
control gene G6PD. The samples and the reaction mix were pipetted in to three different 
96-well plates as triplicates of each sample. 96-well microtiter plate plan for qPCR is 
demonstrated in Appendix 5. For quantitative PCR, 51 PCR rounds per plate and Taq-
Man method was used. The qPCR was performed by LightCycler 480 Roche Diagnostics 
Oy machine.  
4 Results 
 
Gained results indicate first of all that MYB gene is expressed in these studied GIST cell 
lines. Furthermore, the drug imatinib and MYB siRNA reduces MYB protein and MYB 
RNA levels in these cancer cells, at least in cell line 882. This reduced development on 
protein level is visually seen in western blot picture results and on RNA level calculated 
from qPCR results. 
 
4.1 Western blot 
 
Western blot pictures were taken after 45 seconds of exposure and after 30 seconds of 
lightning exposure. The clearest image was captured on 45 seconds in imatinib western 
blot membranes and in 30 seconds of siRNA transfected western blot membranes. It 
was known beforehand that MYB produced protein’s molecular weight is seen in the 
pictures round 80kDa and that way it was able to detect it from unspecific bands of other 
proteins. The scale of different kDa was created by using ladder bands that marked dif-
ferent spots of kDa. Also, for control jurkat that has the same 80kDa spot to stop in 
western blot was used. 
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4.1.1 Imatinib treated cells  
 
For imatinib western membranes, non-treated cells as controls with the imatinib treated 
cells were used. That way it was possible to determine the wanted specific band of MYB 
protein with the ladder bands and with the control band Jurkat. As shown in Picture 5, 
the band is the lower one of two closely settled bands. In cell line 882, the drop or fading 
of the band in the imatinib treated cells is clearly visible in 24 hour bands (IM1) and in 48 
hour bands (IM2). Actin protein was also blotted to make sure there were enough and 
evenly protein loaded in the wells in the early stage of western blotting. Unfortunately, in 
the first of 24 hour bands of line 882, there was not enough protein loaded so the picture 
seems over lightened.  
 
In cell line 48 this fading of bands is not as clearly seen as in 882. The troubles of the 
cell culture in 48 and getting cells co-operate in the wanted way was not as successful 
as was hoped. For that reason, results are based merely in the results of cell line 882 
not in the cell line 48. 
Picture 5.    GIST882 and GIST48 imatinib treated western blot  
4.1.2 siRNA transfected cells 
 
In siRNA transfection, control siRNA, MYB siRNA and KIT siRNA transfection were used. 
Ladder and Jurkat cell lysate were used to identify the right MYB band. Control, scram-
ble, was there to work as negative control just to see that MYB protein band existed in 
cultured GIST cells. KIT siRNA was there to work as the positive control, where it was 
known to fade because imatinib effect is mediated through KIT receptor in GISTs.  
 
As seen in Picture 6, the lower band is the MYB protein band and there is a slight fading 
in the MYB siRNA (marked as MYB in the picture) bands compared to the negative con-
trol in cell line 882. As for the KIT siRNA, the band did not fade as it was estimated to. 
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There might have been something wrong in the KIT siRNA that it did not work here as 
supposed to. Although, in the earlier footage (not shown here), the fading of KIT was 
clearly seen in transfected cells. Those pictures were otherwise unusable due to too 
many unspecific bands in the western blot picture. In Picture 6 is also seen the fact that 
in cell line 48 there are not any clear fading of the bands. Mostly this results from same 
reasons as in imatinib treated 48 GIST cells. 
 
Unfortunately, the western blot picture from the siRNA membranes was first full of un-
specific bands and was too unclear to determine the wanted MYB band could not be 
clearly seen. For this reason the transfection was redone with T25 flasks with the same 
protocol to get more cells and more protein for western blotting to gain proper results. 
The result here are from the T25 flasks.  
Picture 6.    GIST882 and GIST48 siRNA transfection western blot  
4.2 qPCR 
 
RNA level results were gained from quantitative PCR. From each differently treated cell 
group, there were duplicates or triplicates used in qPCR. Because of the minor amount 
of studied subjects, no statistical analysis could be performed to the results. Neverthe-
less, the results were gathered as graphic presentations. Vertical scale in the graphs 
represent the mathematical figures of MYB gene’s RNA compared to control G6PD 
gene’s RNA as a relative presentation. Figures from the qPCR are demonstrated in Ap-
pendix 5. 
 
4.2.1 GIST 882 
 
In the shown graphics there are two groups compared with each other. For validating, 
the cells were separated before any treatments from the 24-well plate (left column in the 
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graphics) and after 48 hours of cell culturing (right column in the graphics). For the vali-
dation to be accurate, the amount of MYB produced RNA should have been similar be-
tween compared groups. This way would have been proved that the MYB produced RNA 
is standard on non-treated and in non-transfected cells in a cell culture. Unfortunately, 
because of the difficult process to get the cells lysed carefully, there were not enough 
cells from the before treatments point. For this reason, demonstration in the shown 
graphics is not acceptable for proper validation. Instead of two compared groups being 
on the similar level, there is more used cells and therefore more MYB response in 48 
hour control. This way the validation did not work as it should’ve worked. Gained MYB 
results were proportional to the housekeeping gene G6PD that has a known standard 
expression. Validation for line 882 cells is demonstrated in Picture 7 as a histogram and 
as a box plot. Scale in histograms is from 0 to 2,0 and in box plots differs depending on 
graph.  
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Picture 7. Validation graphic presentation for line 882 cells. For validation, before treatments and non-treated cells on 48 hour mark, were compared with each other. Mean values, of RNA result groups, were compared with each other. Validation is demonstrated as a histogram and as a box plot on a same scale. Validation is not accurate, because the amount of MYB produced RNA is different in compared groups.  
In the graphic of non-treated cells at 48 hour mark and imatinib treated cells, there is 
numeral decreasing of MYB produced RNA. Therefore, it can be said that imatinib has 
decreased the expression of MYB in RNA level in GIST cell line 882. On figures the drop 
of MYB produced RNA is from 1,3014 to 0,3131 after 48 hours of cell culturing. The effect 
of imatinib to GIST cell line 882 is seen in Picture 8. The left column represents non-
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treated cells after 48 cell culturing and the right column represents imatinib treated cells 
after 48 hours of cell culturing. The same decreasing is represented as a histogram and 
as a box plot.   
 
     
 
Picture 8. Graphic presentation of effect of imatinib for line 882 cells. Non-treated cells on 48 hour mark and imatinib treated cells on 48 hour mark, were compared with each other. The imatinib treatment decreased the amount of MYB produced RNA significantly from 1,3014 to 0,3131 RNA. Mean values, of RNA result groups, were compared with each other. Effect of imatinib to cell line 882 cells is demonstrated as a histogram and as a box plot on a same scale.  
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As for the effect of MYB siRNA for cell line 882, non-transfected cells on 48 hour mark 
and MYB siRNA transfected cells on 48 hour mark were compared with each other. The 
graphic shows that MYB siRNA decreases the amount of RNA compared to non-trans-
fected line 882 cells. Non-transfected cells on 48 hour mark are represented on the left 
column and MYB siRNA transfected cells on 48 hour mark are represented on the right 
column in the graphics. On figures this decrease or drop of the amount of RNA is from 
1,145 to 0,5968. The effect of MYB siRNA in cell line 882 is demonstrated in Picture 9. 
The same decreasing is represented as a histogram and as a box plot.  
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Picture 9. Graphic presentation of effect of MYB siRNA for line 882 cells. Non-transfected cells on 48 hour mark and MYB siRNA transfected cells on 48 hour mark, were compared with each other. The MYB siRNA transfection decreased the amount of MYB produced RNA significantly from 1,145 to 0,5968 RNA. Mean values, of RNA result groups, were compared with each other. Effect of MYB siRNA to cell line 882 cells is demonstrated as a histogram and as a box plot. Box plot has a different scale compared to histogram.  
 
 
 
1,145
0,5968
00,2
0,40,6
0,81
1,21,4
1,61,8
2
Non-transfected cells at 48 hour mark MYB siRNA transfected cells at 48hour mark
MYB siRNA transfection in cell line 882
30 
  
4.2.2 GIST 48 
 
In validation for cell line 48 cells were compared in before treatments group with non-
treated cells on 48 hour mark. In line 48, cells were easier to remove from the before 
treatments plate (than in line 882), but the amount of cells decreased from unknown 
reason after 48 hours of culturing. This might have affected of the amount of cells that 
were lysed in 48 hour cell culture 24-well plate. Overall, there were not much line 48 cells 
to begin with due to poor cell growing of line 48 cells in 24-well plate. This might indicate 
that the measured amount of MYB produced RNA is larger in before treatments mark 
than in non-treated 48 hour in mark in the validation graphic. Cell amount is not usually 
the reason behind qPCR results, because in relative qPCR studied gene (MYB) is com-
pared to housekeeping gene (G6PD). Results are a reflection from the ratio between 
these two genes. Nevertheless, in this case the validation did not work as it was intended 
to work. Validation therefore should not be trusted neither in line 882 cells nor in line 48 
cells. Validation for cell line 48 is demonstrated in Picture 10. Validation is represented 
as a histogram and as a box plot.   
31 
  
     
 
Picture 10. Validation graphic presentation for line 48 cells. For validation, before treatments and non-treated cells on 48 hour mark, were compared with each other. Mean values, of RNA result groups, were compared with each other. Validation is demonstrated as a histogram and as a box plot. Validation is not accurate, because the amount of MYB produced RNA is different in compared groups. Box plot has a different scale compared to histogram.  
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Between imatinib the non-treated cells on 48 hour mark and imatinib treated cells on 48 
hour mark, there was a minor drop of MYB produced RNA level in line 48. However, the 
decreasing of MYB produced RNA in imatinib treated cells is extremely small or hardly 
recognisable. Hence, the imatinib drug did not have the hoped effect on cell line 48 nei-
ther on RNA level in qPCR nor on protein level in western blot. The 48 cells did not grown 
properly and were forced, for the reason of limited amount of time, to be lysed before 
optimal confluence. This might be the major reason why the results from line 48 are not 
coherent with the expected reaction. The effect of imatinib in line 48 cells is demonstrated 
in Picture 11. The effect of imatinib is represented as a histogram and as a box plot.  
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Picture 11. Graphic presentation of effect of imatinib for line 48 cells. Non-treated cells on 48 hour mark and imatinib treated cells on 48 hour mark, were compared with each other. The imatinib treatment decreased the amount of MYB produced RNA in extremely minor amount, practically not at all, from 0,2085 to 0,2064 RNA. Mean values, of RNA result groups, were compared with each other. Effect of imatinib to cell line 48 cells is demon-strated as a histogram and as a box plot. Box plot has a different scale compared to histogram.  
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Effect of MYB siRNA for line 48 cells was noticed by comparing non-transfected cells on 
48 hour mark with transfected cells on 48 hour mark. There was a minor decreasing in 
MYB produced RNA in MYB siRNA transfected cells compared with non-transfected 
cells. Nevertheless, the decrease is quite small and therefore it is not significant. Results 
from qPCR in line 48 indicate the same as did the results from western blotting in line 48 
cells. Due to difficulties met in the process of growing line 48 cells, especially for qPCR, 
noteworthy results were only gained from line 882 cells. Effect of MYB siRNA in cell line 
48 is demonstrated in Picture 12. The effect is represented as a histogram and as a box 
plot.   
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Picture 12. Graphic presentation of effect of MYB siRNA for line 48 cells. Non-transfected cells on 48 hour mark and MYB siRNA transfected cells on 48 hour mark, were compared with each other. The MYB siRNA transfection decreased the amount of MYB produced RNA in minor amount from 0,2466 to 0,1858 RNA. Mean values, of RNA result groups, were compared with each other. Effect of MYB siRNA to cell line 48 cells is demon-strated as a histogram and as a box plot. Box plot has a different scale compared to histogram.  
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5 Discussion 
 
In this study, cell culturing was based on aseptic work methods. GIST cells were cultured 
in suitable environment (RPMI base). Heat inactivated FBS and suitable antibiotics were 
added into the used medium of the cell culture. Cells were maintained by dividing them 
and by changing the medium on regular basis. To this cell growth environment, imatinib 
was added and incubated 24 or 48 hours to let it effect on the cells of the culture. Small 
interfering RNAs were transfected to the cells by using Lipofectamine 2000 reagent. After 
the transfection, cells were left for 48 hours before any further tests could be performed 
that the gene or protein expression had time to fade. Every step in this study was marked 
down in to the laboratory notes.  
 
In the cell culture most of the used reagents and used materials were new and were not 
expired. Only the inhibitors used in RIPA buffer were expired in the year 2015. Culturing 
was performed by following aseptic regulations and in proper conditions for cell culturing. 
Cells or sterilized materials/reagents contacted with cells, were only handled in sterilized 
laminar flow hood with sterilized gloves and medium among other reagents was always 
warmed to +37 °C before use. Used cell lines were kept in -150 °C in DMSO reagent to 
retain their morphological and physiological features. DMSO was deactivated and 
washed with PBS before the actual transfer and starting of cell culture in flasks filled with 
growth medium. Cells were kept during their culture period in incubator cabinet at +37 
°C with 5 % of carbon dioxide. The adding of imatinib and the siRNA transfections were 
performed following the given and planned instructions of the research team (working 
protocol in Appendix 2). The procedure of western blotting went according to the used 
protocol (seen in Appendix 3).  
 
References were mainly used in this study for the background of GIST, MYB gene and 
for the theory of used methods. Most of the used references were from different research 
articles and from different books concerning laboratory methods. Some of the information 
in the used sources might have been out to date due to new research on the GIST and 
MYB field. Nevertheless, the information in the used articles was relevant to this study 
and mainly from this century. The information in the book sources was accurate in de-
scribing the laboratory techniques used in this study. Techniques were straight forward, 
well studied and formed to be so called basic techniques in modern laboratories. This 
study did not require any ethical permissions et cetera because the used materials did 
not require any patient obligation to maintain secrecy as no direct patient samples were 
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used, no animal testing included nor genetically modified organisms were included in this 
study. All the permissions needed to conduct this study were handled and possessed by 
the research group of Heikki Joensuu. However, some ethical concerns in this study 
might have been the problems of ‘creating’ or growing new cancer cells which was done 
in a controlled environment. Some environmentally harmful materials were used for ex-
ample β-mercaptoethanol, but all these kind of materials were stored and disposed ac-
cording to the given manufacturer’s instructions.  
 
This being said, the protocol for this research took time to find and form to gain proper 
usable results. There was a lot of fixing in many parts such as finding the right lightning 
exposure time, right chemiluminescent substrates, loading the right amount of protein, 
right concentration for the used antibody et cetera. 
 
There were notable differences between the two used cell lines. Firstly, the line 882 grew 
in the cell culture quite fast and were morphologically larger cells than line 48 cells. Sec-
ondly, the line 882 seemed to react less to changes than line 48. All throughout the 
process the line 882 was more manageable than the line 48. Line 48 had small cells that 
grew differently depending upon the surface, for example they grew better in big flasks 
rather than in 6- or 24-well plate. Also line 48 cells, were easily damaged by changes in 
environment. Especially in the used 24-well plate for qPCR cells should have been cul-
tured in different plates rather than on the same plate. Merely this, because line 882 cells 
had to be lysed line 882 before the line 48 cell due to the slow growth of line 48 and due 
to the fast growth of 882. This being said, the cells from 48 were removed few times from 
the incubator. The harm in doing so can be witnessed in line 882 as it was almost im-
possible to get enough cells from the plate while trying not to damage line 48 cells at the 
same time. This can be seen in pictures 7 and 10 of qPCR validation graphic demon-
stration (the columns should be on the same level rather than the other one being smaller 
in numbers).  
 
There might have been unknown contaminations, too many passages, unique cell be-
haviour or some other changes in growth that effected the line 48 not to grow properly. 
Some of the reasons might have contamination of mycoplasma, of virus or wrong atmos-
phere for line 48 cells to grow. There might be also some problems in transfection or 
reaction to the imatinib drug why the results from the line 48 are not the searched results. 
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Additionally, problems in cell culture may reflect from unexperienced working in cell cul-
ture. These are the main reasons why there are only proper usable results from line 882 
for this study. 
 
As mentioned earlier the used inhibitors for RIPA buffer were out of date during this 
study. Nevertheless, it did not seem to have any major effect on cell lysis from the surface 
of flasks or plates. Inhibitors prevent enzymes for example proteases form breaking the 
wanted proteins in cell lysis. Cells were lysed on an ice bath and overall lysed by follow-
ing the given instructions of the research team (demonstrated in Appendix 2). This being 
said, it was humanly impossible to get every single cell off from the cell culture bases. 
Despite that, all those cells that could be removed were removed under the given cir-
cumstances. Unfortunately, this might be seen in results as too little cell material.  
 
After lysis, the breaking of cell structures was performed by using the sonic prep machine 
that breaks the structures using high pitch sound waves. The breaking was done in parts 
for ten seconds two times per each lysed cell sample in Eppendorf tube. Cells for western 
blotting did not react badly to this and were able to be in the sonic machine for the wanted 
10 seconds’ time. Cells used for qPCR however reacted fast to the sound waves and 
turned white quite quickly. Turning white indicated the breaking of also the smaller parts 
for example proteins in cells, which was not the meant reaction when only the larger 
parts were meant to brake. This might have occurred because of the smaller amount of 
cells from the used 24-well plate instead of T25 flasks in the case of western blotting. 
For this reason, the preparation for qPCR cells was only few seconds per Eppendorf 
tube. This is why there maybe were not enough material to be isolated and that might be 
part of the reason why small amounts of RNA was used. More RNA might have given 
the way to get more samples and more triplicates from those samples for the qPCR, 
which would have given the opportunity for statistical analysis.  
 
The lysed cells were kept in -70 °C and then thawed for used. Because of the search for 
the right protocol some lysed samples had to be thawed few times. This might have 
affected the samples (some unwanted biochemical reactions may have occurred during 
the process). Samples were nevertheless thawed on an ice bath to avoid any harmful 
biochemical reactions. To measure the amount of protein for western blotting, absorb-
ance method in measuring the total protein amount was used. The samples were com-
pared to the made protein standards provided by the used protein measurement kit (seen 
in Appendix 5). The measuring had to be performed few times because there were too 
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significant differences between duplicates in the measured samples. The difference orig-
inated from inaccurate pipetting. Approved and left results can be seen in Appendix 5. 
Due to these problems the approved results were not as accurate as wanted in total 
protein amounts (which would have been under 10% difference between duplicates). 
Overall, absorbance results told the round number of total protein in the lysed samples. 
These results were used in loading the samples in SDS-PAGE gels in western blotting. 
 
β-mercaptoethanol was added to the lysed cells for denaturing the protein structures of 
the cells and the samples were boiled in +100 °C for ten minutes. After the denaturation, 
the samples were ready to be loaded in to the SDS-PAGE gel. Overall the denaturation 
and gel loading went according to the protocol. Neither there were any problems in gel 
electrophoresis nor in building the so called ‘sandwich’ for electroblotting the proteins 
from the gel into the PVDF membrane. Samples were thoroughly washed with washing 
buffer between antibodies and also profoundly kept in the used chemiluminescent. Used 
reagents and materials were up to date and freshly made for this procedure.  
 
The problems laid in antibody concentrations and in the lightning time of used x-ray films. 
First the primary antibody was made to concentration 1:1000 that did not give a proper 
picture. Also the lightning was poor with the used chemiluminescent (one and a half hour 
lightning was not enough). Moreover, it was discovered that the MYB antibody allowed 
only one lightning period with the same chemiluminescent attached to the membrane. 
This is why the chemiluminescent had to be washed from the membranes first and then 
replace the used primary antibody with new one overnight and carry on from there over 
again. Since this protocol did not work, antibody concentration was increased to 1:500 
and lightning time was added up to two to five hours. This protocol gave a slight bands 
which were interpreted that the MYB band could be found from the membranes. The 
bands were too light to say anything about the effects of imatinib or the MYB siRNA. For 
this reason, pico-chemiluminescent was replaced to the femto-chemiluminescent with 
1:500 antibody and quick light exposure. The femto turned out to be extremely sensitive 
so the final results were gained adding 1:3 of femto in pico chemiluminescent, 1:500 
primary antibody, 1:10 000 secondary antibody and 30 or 45 second lightning exposure. 
This complex gave the best results in given time for western blot pictures.  
 
For qPCR the cells were cultured in 24-well plate. The first attempt to culture line 882 
and 48 in 24-well plate did not succeed at all. The cells did not grow or they grew ex-
tremely little so we were unable to use them for the RNA isolation. On the second time, 
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line 882 grew on acceptable level, but the line 48 grew barely at all. Nevertheless, the 
cells were used for control and for imatinib treatment or MYB siRNA transfection. The 
before treatments controls were cultured on a different plate and that might have been 
the reason why they grew more firmly. Although, the line 882 cells were hard to remove 
from the plate. The difficulties emerged, because the line 882 had to be removed from 
the plate earlier than the line 48 (line 48 cells were not in a proper confluence for trans-
mission). 882 cells had to be removed extremely carefully trying not to damage line 48 
cells. This difficulty can be seen in validation graph of line 882 in Picture 7. There were 
not enough cells to gain the wanted validation results. Overall, the cell lines should have 
been cultured on different plates due to the fact that line 48 grew so much slower or 
hardly at all than the line 882. This fact had effect on both of the lines. It was unable to 
get line 882 cells enough to get better results and line 48 cells did not appreciate the 
moving around from the incubation storage. The cells were stored in -70 °C before the 
RNA isolation. 
 
RNA isolation was performed according to Machery-Nagel’s RNA silica isolation proto-
col. Due to mistake in washing part of the silica method, the RNA was washed multiple 
times to ensure the purity of RNA. Accidentally Buffer 3 was used raw instead of diluting 
it in to ethanol. The mistake was fixed by washing the cells multiply times with ethanol 
before diluting them into sterile RNAase free water. After the elution, the purity and con-
centration of RNA was measured by using the absorbance of 260nm. Purity of the RNA 
varied from 1,53 ng/µl to 2,12 ng/µl (seen in Appendix 5) and the yield of RNA in the 
actual samples (not in the control) varied from 2,5 to 23,5 (Appendix 5). After the isolation 
RNA was transferred to cDNA for qPCR. The amount of the used RNA template was 
determined by the yield of RNA. Under 10ng had 15µl of template and 60µl of reaction 
mix; from 10ng to 16,4ng had 7µl of template and 28µl reaction mix and 49µl sterile 
water; and lastly over 16,4ng had 12µl of template and 48 reaction mix and 132µl sterile 
water. The transfer from RNA to cDNA was performed with Dyad Disciple machine ac-
cording to the given program (Appendix 4). After the transfer the samples were ready for 
quantitative PCR.  
 
For qPCR the samples were divided with the control sample and with water control for 
three different 96-well plates (for MYB and G6PD). Overall there were 211 samples for 
the qPCR. The used MYB primers were in a 100 µM stock each and were diluted in a 
ratio 1:10. For each well 1µl of sample and 19µl of reaction mix was pipetted. All of the 
96-well plates were pipetted and run during one day. For that reason, there is a possibility 
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for human errors in pipetting the samples and the reaction mix. Moreover, the possibility 
for human errors increases in small amounts of pipetting per one well (1µl of sample). 
The procedure was done according to aseptic working methods in a fume hood to avoid 
any contaminations of the samples. The plates were analysed in 1,5 hours per plate. In 
few triplicate samples the results were not usable for unknown reason in the working 
period. Those samples might had some contamination, not the right amount of sample 
in the plate, mistakes in calculation of the sample or there were so little of the sample to 
begin with that no proper results could’ve be gained (samples non-treated cells and MYB 
siRNA transfected in 48 and also siRNA control in line 882). 
 
Overall, there might be too few results in numbers to say anything absolute certain about 
the effect of imatinib or MYB siRNA. In western blotting, two time points and duplicates 
though indicate clearly the effect of the drug imatinib in line 882. The diminish of the 
estimated MYB protein signal can be visually seen to fade in both time points (24 hours 
and 48 hours of imatinib treatment). This way the results gave an answer to one of the 
hypothesis of this study. On the other hand, in the qPCR it was not able to use any 
statistical methods due to the fact that there were few triplicates or duplicates used. To 
gain statistical proof of RNA level action or drop of the MYB coded mRNA, there should 
be larger quantity of samples to get statistically significant results. Two or three samples 
can only tell part of the truth about the RNA level effects on MYB in the case of imatinib 
or MYB siRNA. 
 
This study succeeded well despite of all the difficulties met throughout this project. Main 
strengths – motivation, eagerness and interest in the subject – helped me concentrated 
in the actual working with the MYB antibody. Moreover, my quite short schedule com-
pared to this project kept me concentrated all the time throughout this year. Generally 
well planned schedule and organizing time worked satisfactorily. There were minor mis-
haps in the planned schedule due to the difficulties of MYB antibody and due to other 
university of applied sciences or work projects that were simultaneous with this thesis. 
Overall I learned a lot about cancer research and working rhythm in a research group. 
Also I gained a lot of new knowledge about genes and their linkage in different cancers. 
All the previous knowledge from my degree programme in biomedical laboratory science 
was brought to use in this project. Additionally, I grew tremendously as a biomedical 
laboratory scientist due to this thesis.  
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Regardless of difficulties with the cell line 48 and special working conditions with Millipore 
MYB antibody, proper results were gained from this study. The results indicate that there 
is a meaning of MYB expression concerning gastrointestinal stroma tumours. It is also 
interesting that the drug imatinib is seen to decrease the protein and the RNA production 
of MYB in these cells. MYB siRNA had effect also in the GISTs cells despite the fact that 
siRNAs rarely transfect 100% to cells. Results were gained from cell line 882 concerning 
imatinib’s effect decreasing the production MYB transfection factor. Results from used 
MYB siRNA in line 882 were bit difficult to interpret due to the lack of expected KIT siRNA 
reaction, but they do give some kind of protein and RNA decrease in the results. More-
over, the creation of a proper and working protocol for MYB antibody was made during 
this study. This way it can be used more effectually in the future research of MYB gene.  
 
There are some things that affected this study that should or could have been done bet-
ter. The used Millipore MYB antibody was not tested before it was tested in this study. 
This was the main reason that affected the schedule and took more time in the laboratory 
than expected. There were problems in the right concentration of antibody and the right 
lightning time of western pictures. The fact that MYB antibody had to be washed off be-
fore taking new pictures from the same membranes was a problem. Additionally, there 
were problems with the finding of right chemiluminescent for the western pictures. It took 
several weeks to form a proper working protocol to gain usable results, which for its own 
part took time from for example the qPCR. With more time there could have been more 
samples to qPCR to gain results that could have been analysed with statistical methods. 
Statistical analysis would have given more trustworthy results about RNA level MYB 
gene function in GIST cancer cells. Unnecessary time consuming things were also re-
running the protein measurements and the difference in speed of growth between line 
882 and line 48. Moreover, the amount of samples in qPCR demanded lot of concentra-
tion but had to be performed during one day. If there would have been more time, there 
maybe would not have been mistakes or possible contaminations in some of the qPCR 
samples.  
 
The diminish of MYB protein and RNA signal, especially in imatinib treated line 882 cells, 
indicate that imatinib has effect of MYB gene expression and that gene expression is 
seen in GIST cancer cells. Further meaning of this requires more research in the field of 
MYB linkage of GIST cancer and especially MYB linkage to for example KIT gene. When 
imatinib is known to effect KIT mutation positive GIST cells, does these results indicate 
that MYB might control KIT gene expression? Is MYB really the main super enhancer to 
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downstream genes in GIST such as KIT? In the research group of Heikki Joensuu next 
steps in MYB research are to find out the effect of imatinib in downstream genes of MYB 
for example KIT, SLUG and stem cell factor. Moreover, the research group is going to 
find the answers to other questions, such as does MYB positive tumour patients have 
worse survival prediction? Does MYB gene expression effect on imatinib response? 
Could GIST tumours be treated with inhibiting MYB expression? Answers to these ques-
tions need foundation for GIST patient-drug testing and further research on cell level for 
example to study effect of reducing protein signals of MYB and seeing how it affects 
other genes or on other genes expression in proliferation of cancer cells.  
 
Gaining knowledge of the genetic origins of cancer can be the foundation of genetically 
targeted cancer treatments. MYB could be one of the possible targets for personalized 
cancer treatments. Hopefully, this thesis could work as a part of targeting MYB in the 
future. Naturally, more research around MYB subject must be conducted before any 
treatments can be verified. In near future, these genetically targeting treatments might 
be seen playing a significant role in different cancer therapies.  
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Reagents and materials 
 
Cell culture medium 
 
Product REF/ Cata-
logue number 
LOT Exp. Storage 
Gibco – RPMI 
Medium 
31870-025 1737520 2017/12 +4 °C 
Gibco – Peni-
cillin Strepto-
mycin Gluta-
mine 
10378-016 1677652 2016/02 -20 to +5 °C 
Gibco – Fetal 
Bovine Serum: 
inactivated at 
+56 °C 
10270-106 41Q6841K 2019/09 -20 to +5 °C 
 
Cell culture  
 
Product REF/ Cata-
logue number 
LOT Exp. Storage 
Lonza - Trypsin 
x10 
BE02-007E 4MB146 2018/09 < -10 °C 
Sigma - DMSO 
(Dimethyl 
sulphoxide) 
D2650 RNBC9661 2016/07 Room temp. 
Thermo Fisher 
Scientific – 
Pierce RIPA 
buffer 
89901 QH220396 Not known +4 °C 
Thermo Fisher 
Scientific –
Pierce Phos-
phatase Inhibi-
tor 
88667 OF189628 2015/05 +4 °C 
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Thermo Scien-
tific – Pierce 
Protease inhibi-
tor: AEBSF, 
E&¤, Leupep-
tin, Aprotinin, 
Pepstatin A and 
Bestatin 
88666 OJ194838A 2015/01 +4 °C 
Gibco – Opti-
MEM: Reduced 
Serum Medium 
31985-047 1722740 2016/10 +2 to +8 °C 
Invitrogen - 
Lipofectamine 
Invitrogen Rea-
gent 
11668-019 1692389 2017/05 +2 to +8 °C 
Gibco – L-Glu-
tamine 200mM 
25030-024   -20 °C 
Dharmacon – 
ON-TARGET 
plus Control 
pool  
Non-Targeting 
pool 
D-001810-05 1993609 opened 
020316 
-20 °C 
Dharmacon - 
ON-TARGET 
plus SMART 
pool Human 
MYB 
L-003910-00 150708 opened 
310815 
-20 °C 
Dharmacon – 
ON-TARGET 
plus SMART 
pool 
Human KIT 
L-003150-00 160121 opened 
020316 
-20 °C 
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Gibco – Trypan 
Blue Stain 
(0.4%) 
15250-061 1756514 2018/12 Room temp. 
Thermo Scien-
tific – Easy 
Flask 75 Filt 
 145060 2020/08 Room temp. 
Cellstar – 6 
Well Cell Cul-
ture Plate ster-
ile with lid 
657 160 E14103J7 2018/10 Room temp. 
Costar – 24 
Well Cell Cul-
ture Cluster: 
Flat Bottom 
with Lid: 
Nonpyrogenic: 
Polystyrene 
    
Lancrix – 
Imatinib mesyl-
ate 99%+ 
147881 130305 Not Known Cool and dry 
Amresco – Wa-
ter, Sequencing 
grade 
K683-25ml 1104C176  Room temp. 
 
Western blotting 
 
Product REF/ Cata-
logue number 
LOT Exp. Storage 
Thermo Scien-
tific – Pierce 
BCA Protein 
Assay Kit: In-
cludes reagent 
A and B and 
also Albumin 
Reagent A:  
23228 
Reagent B: 
1859078 
Standard: 
23209 
P1208796 Not Known Room temp. 
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standards from 
bovine serum 
Bio Rad – 2x 
Laemmli Sam-
ple Buffer 
161-0737 L004126A 2017/10 Room temp. 
Sigma chemi-
cals – β-mer-
captoethanol 
C2H2OS 
M-3148 95H092315  Room temp. 
Bio Rad – 1x 
SDS buffer: Di-
luted 10x 
TRIS/Gly-
cine/SDS-
Buffer 
161-0732 Not known 2015/11 Room temp. 
1x Transfer 
Buffer: Diluted 
10xTBS, tween 
added. 24,2q 
Tris Base, 80,0 
g NaCl and 
13,5 ml 37% 
HCl in 1 liter of 
MQ H2O 
    
Bio Rad – Mini-
Protean TGX 
Precast Gels: 
10%, 10-well-
comb, 50 
µl/well 
456-1034  2016/10 +2 to +8 °C 
BioRad – Pre-
cision Plus 
Protein Dual 
Color Stand-
ards (Ladder) 
161-0374 ctrl 64022882 2017/09 -20 °C 
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Temecula - 
Jurkat Cell Ly-
sate (T-Lym-
phocyte cell 
line) 
 2500604  -20 °C 
Fisher Chemi-
cal – Methanol 
Analytical rea-
gent grade 
 1666182 Packing date: 
270116: Use 
within 5 years 
of opening 
Room temp. 
Millipore – 
Anti-Myb, 
clone 1-1: 
Monoclonal 
antibody 
05-175 2605462  -20 °C 
Jackson Im-
muno Re-
search – Per-
oxide-conju-
gated Affini-
pure Rabbit 
Anti-Mouse 
IgG 
315-035-003 65710  -70 °C 
Valio – Rasva-
ton maitojauhe 
    
Sigma – Pon-
ceau S Solu-
tion 0.1%: Pon-
ceau S (w/v) in 
5% acetic acid 
(v/v) 
025K4355  Opened: 
21.9.2005 
Room temp. 
Thermo Fisher 
Scientific – Su-
persignal West 
Pico Chemilu-
minescent 
34080 QH220527 Not Known Room temp. 
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Subsrate: Con-
tains: Stable 
peroxide and 
Luminol/ En-
hancer 
Thermo Fisher 
Scientific – Su-
persignal West 
Femto Maxi-
mum Sensitiv-
ity Substrate 
34095 QG21978413 Not Known Stable in room 
temperature 
for 6 months. 
Longer storage 
in +4 °C 
Thermo Scien-
tific – Nuclon 
Delta Surface 
96 well plate 
Sterile 
167008 145551 Not Known Room temp. 
Bethyl – Rabbit 
anti-Cytoskele-
tal Actin Affinity 
Purified: 100ul 
at 1mg/ml 
A300-491A   +2 to +8 °C 
Jackson Im-
muno Re-
search – Per-
oxide-conju-
gated Affini-
pure Goat Anti-
Rabbit IgG 
111-035-003 108536  -70 °C 
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RNA protocol 
 
Machery-Nagel – 
NucleoSpin RNA 
740955.50 1506/006 Not known Room temp. 
Roche - Light Cy-
cler 480 Probes 
Master (Probe mix 
and H2O for qPCR) 
04887301001 Not known Not known Store at -15 
to -25 °C 
Roche – Universal 
ProbeLibrary Hu-
man G6PD Gene 
Assay: Probe 
05046246001 091824 2015/06 Store in dark 
at -15 to -25 
°C 
Roche – Universal 
ProbeLibrary Hu-
man G6PD Gene 
Assay: Primer 
050462466001 100180 2016/08 Store at -15 
to -25 °C 
Roche – Universal 
ProbeLibrary: 
Probe #54  
0468851001 701237  Store at -15 
to -25 °C 
Oligomer – 
MYB_LNA#54_For-
ward primer 
160323B067B11   Store at -15 
to -25 °C 
Oligomer – 
MYB_LNA#54_Re-
verse primer 
160323B067C11   Store at -15 
to -25 °C 
Bio-RAD – iScript 
cDNA Synthesis Kit 
170-8891 ctrl 64063853 2018/01 -20 °C 
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Working protocol for cell culture 
By research group of Heikki Joensuu 
 
Cells from freezer to flasks 
 
1. Divide medium to two T75 flasks 15ml per each flask. Place them in to the incu-
bator +37 °C and 5% CO2 to settle for 15 minutes. 
2. Pick the cells from -150 °C and melt the suspension in Eppendorf tube quickly in 
warm water +37 °C.  
3. Add 5 ml of medium to the cell suspension in falcon tube. Make sure that all the 
cells from the Eppendorf tube are mixed with the medium.  
4. Centrifuge the falcon for 7 minutes in 1000 rpm. 
5. Remove the medium from the cells and add 1 ml medium on top of the cells. Mix 
the cells and 1 ml medium carefully by pipetting few times. 
6. Take the T75 flasks from the incubator and add 500 µl cell suspension per flask. 
7. Place them back in to the incubator and monitor after few days how the cells have 
started to grow. 
 
Dividing cells 
 
1. Cells should be at least in 70 to 80 % confluence before dividing them in micro-
scope. 
2. Remove the medium from cells and wash them with 10ml PBS solution. 
3. Remove the PBS and add trypsin on top of the cells, e.g. 2ml trypsin to GIST48 
and 3ml trypsin to GIST882. 
4. Place the flasks in to the incubator for 5 to 10 minutes.  
5. Take the flasks out and tap the sides of flasks a bit to remove the cells from the 
surface of the flasks. 
6. Add medium to the cells so that the total volume in flask is 10 ml. Rinse the sur-
face of the flask with the medium and remove the suspension with trypsin and 
medium in to falcon tube. 
7. Centrifuge the falcon for 7 minutes in 1000 rpm. 
8. Remove the media from the falcon and add 1 ml of medium on top of the cells. 
Mix the cells and 1 ml medium carefully by pipetting few times. 
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9. Divide the cells into new flasks with 15 ml of medium, e.g. 500 µl in 1:2 or 333 µl 
in 1:3. If divided to smaller T25 flasks, use 5 ml of medium per flask (2 ml medium 
in 6 microtiter plate and 500 µl medium in 24 microtiter plate). 
10. Place flasks into the incubator.  
 
Imatinib treatment to cell culture 
 
1. Prepare wanted concentration for imatinib by diluting it to the used RPMI medium 
from 10mM stock into 0,5µM (2,5 µl stock and 50ml of medium). 
2. For the control cells change medium normally to the T25-flasks (5ml). 
3. For the imatinib treated cells change medium by using the prepared 0,5µM 
imatinib medium (5ml). 
4. Place the flasks back into the incubator. 
 
siRNA transfection to cell culture 
 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen) 6-well plates  
1. (DAY 0) Seed cells in 2 ml antibiotics-free growth medium. Cells should be ~30-
50% confluent before starting transfections.  
2. (DAY 1) Remove growth medium.  
3. Wash the cells with 2ml PBS.  
4. Add 2 ml of Opti-MEM medium to the cells and let the cells starve ~6 h.  
5. Take the siRNAs on the ice.  
6. Mix Lipofectamine before use by pipetting. Dilute 2,5 µl Lipofetamine in 250 µl 
Opti-MEM. Mix by pipetting.  
7. Mix siRNAs before use by pipetting gently. Dilute 5 µl siRNA (20 µM stock) in 250 
µl Opti-MEM  
8. Incubate 5 min at room temp. 
9. Add diluted Lipofectamine to diluted siRNA. Mix by pipetting ~5 times.  
10. Incubate Lipofectamine-siRNA complex 20 min at room temperature.  
11. Remove Opti-MEM from cells. 
12. Add 1ml of antibiotics-free growth medium to cells. 
13. Add Lipofectamine-siRNA complex (500 µl) to the cells.  
14. Incubate cells 24 h at+37°C. 
15. (DAY 2) Incubate cells 24-72 h at+37 °C.  
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16. (DAY 3-5) Visualize/analyze transfected cells.  
 
Reactions are for one well 
 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen) T25 flask  
1. (DAY 0)Seed cells in 5 ml antibiotics-free growth medium. Cells should be ~30-
50% confluent before starting transfections.  
2. (DAY 1)Remove growth medium.  
3. Wash the cells with PBS.  
4. Add 3 ml of Opti-MEM medium to the cells and let the cells starve ~6 h.  
5. Take the siRNAs on the ice.  
6. Mix Lipofectamine before use by pipetting. Dilute 20 µl Lipofetamine in 2ml Opti-
MEM. Mix by pipetting.  
7. Mix siRNAs before use by pipetting gently. Dilute 40 µl siRNA (20 µM stock) in 
2ml Opti-MEM  
8. Incubate 5 min at room temp. 
9. Add diluted Lipofectamine to diluted siRNA. Mix by pipetting ~5 times.  
10. Incubate Lipofectamine-siRNA complex 20 min at room temperature.  
11. Remove Opti-MEM from cells. 
12. Add 2 ml of antibiotics-free growth medium to cells. 
13. Add Lipofectamine-siRNA complex (1 ml) to the cells.  
14. Incubate cells 24 h at+37°C. 
15. (DAY 2) Incubate cells 24-72 h at+37°C.  
16. (DAY 3-5) Visualize/analyze transfected cells.  
 
Reactions are for one well 
 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen) 24-well plates (for 1 well) 
1. (DAY 0) Seed cells in 500µl of growth medium without antibiotics. Cells should 
be ~70-90% confluent before starting transfections.  
2. (DAY 1)Remove growth medium.  
3. Wash the cells with PBS.  
4. Add 500µl of Opti-MEM medium to the cells and let the cells starve ~6 h.  
5. Take the siRNAs on the ice. 
Appendix 2 
   4 (4) 
 
  
6. Mix Lipofectamine before use by pipetting. Dilute 1,0 µl Lipofetamine in 50 µl 
Opti-MEM. Mix by pipetting gently. 
7. Mix siRNAs before use by pipetting gently. Dilute 1,0 µl siRNA (20 µM stock) in 
50 µl Opti-MEM 
8. Add diluted Lipofectamine to diluted siRNA. Mix by pipetting ~5 times and incu-
bate 5 min at room temperature. Proceed the step 7 in 25 minutes! 
9. Add Lipofectamine-siRNA complex (100 µl) to the cells and mix gently by rocking 
the plate. 
10. Incubate cells 24 h at+37°C. 
11. (DAY 2) Replace Opti-MEM medium with normal growth medium including anti-
biotics. 
12. Incubate cells 24-72 h at+37°C. 
13. (DAY 3-5) Visualize/analyze transfected cells. 
 
If the MYB expression is not absent in any time points, siRNA concentration has 
to be optimized next. 
 
Cell lysis 
 
Procedure for Lysis of Monolayer-cultured Mammalian Cells  
Note: If desired, add protease and phosphatase inhibitors to the RIPA Buffer immediately 
before use. (Pierce Protease and Phosphatase Inhibitor Mini Tablets, EDTA Free 1 tablet 
per 10 ml RIPA) 
 
1. Carefully remove culture medium from adherent cells.  
2. Wash cells once with PBS.  
3. Add cold RIPA Buffer to the cells. Use 1ml of buffer per 75cm2 flask containing 
5 000 000 HeLa or A431 cells. Keep on ice for 5 minutes, swirling the plate oc-
casionally for uniform spreading.  
4. Gather the lysate to one side using a cell scraper and collect the lysate into an 
Eppendorf tube. 
5. Sonicate the pellets for 10 seconds per tube.
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Working protocol for western blotting 
By research group of Heikki Joensuu 
 
Procedure for Lysis of Monolayer-cultured Mammalian Cells  
 
Note: If desired, add protease and phosphatase inhibitors to the RIPA Buffer immediately 
before use. (Pierce Protease and Phosphatase Inhibitor Mini Tablets, EDTA Free 1 tablet 
per 10 ml RIPA) 
 
1. Carefully remove culture medium from adherent cells.  
2. Wash cells once with PBS.  
3. Add cold RIPA Buffer to the cells. Use 1ml of buffer per 75cm2 flask contain-
ing 5 000 000 HeLa or A431 cells. Keep on ice for 5 minutes, swirling the 
plate occasionally for uniform spreading.  
4. Gather the lysate to one side using a cell scraper and collect the lysate into 
an Eppendorf tube. 
 
Note: To increase yields, sonicate the pellet for 10 seconds with 50% pulse.  
 
5. Transfer supernatant to a new tube for further analysis. 
 
Measure the protein concentrations with Pierce BCA protein assay KIT 
Mix the sample with LAEMMLI buffer (1/1) 
 
SDS-PAGE 
 
Carry out SDS-PAGE (10% Mini-PROTEAN® TGX™ Gel, 10 well) 
For analytical runs, load 25 to 50 micrograms of protein per well. Apply constant voltage 
at 100 V for max 1.5 hours.  
Running Buffer: Bio-Rad Tris/Glycine/SDS buffer (dilute 10x buffer for 1x buffer) 
Ladder: 4µl Bio-Rad Dual colour ladder.  
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Protein Blotting 
 
1. Build the transfer "sandwich" onto the bright side of cassette as follows: 1 sheet 
foam pad, 1 sheet filter paper, PVDF membrane, gel, 1 sheet filter paper, 1 sheet 
foam pad 
2. Carry out the transfer at 0.15 A overnight at +4°C.  
3. Remove the PVDF membrane from the apparatus (and check the transfer effi-
ciency with Ponceu S).  
 
NOTE: Prewet the PVDF membrane in methanol before it is used (1min). 
NOTE: Prewet the all other membranes in transfer buffer before making the “sandwich”. 
 
Immuno-Detection 
 
1. Block PVDF blot using 5% w/v milk (or BSA) in TBS-Tween 1 h at room temper-
ature. The choice of blocking reagent depends on the type of antibody that will 
be subsequently used in the overlay procedure and should be chosen accord-
ingly.  
2. Remove the blocking buffer.  
3. Wash the blot 3 times for 5 min with TBS-T. 
 
4. Overlay the blot with 20 ml primary antibody at an appropriate dilution (Millipore 
MYB ab: 1% milk 1:1000/ 1:500). 
5. Incubate overnight at +4°C on shaker.  
6. Wash the blot three times for 5 minutes each, with sufficient TBS-T. 
7. Incubate the blot for 1 hour in Rabbit Anti-Mouse IgG -secondary antibody con-
jugate at an appropriate dilution. (1:10 000) in 1% milk).  
8. Wash the blot three times for 5 minutes each, with sufficient TBS-T. 
9. Prepare SuperSignal™ West Pico Chemiluminescent Substrate Working Solu-
tion by mixing equal parts of the Stable Peroxide Solution and the Luminol/En-
hancer Solution (5ml+5ml). Mix it with prepared (1:1) SuperSignal™ West Femto 
Maximum Sensitivity Substrate Working Solution on ratio 1:3 (femto 1:3 and pico 
2:3). 
10. Incubate the blot in the substrate mixture for 5 minutes.  
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11. Remove blot from Working Solution and place it in a plastic membrane protector; 
a plastic sheet protector or plastic wrap may be used. Place the protected mem-
brane in a film cassette with the protein side facing up.  
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Working protocol for quantitative PCR 
By research group of Heikki Joensuu 
 
RNA isolation 
 
RNA isolation was performed according to Machery-Nagel user manual of RNA isolation 
version User manual NucleoSpin® RNA XS 2014.  
 
RNA transfer to cDNA 
 
1. Measure the purity and concentration of isolated RNA by using e.g. spectropho-
tometer. 
2. Prepared iScript cDNA mix and sterile water are combined with the RNA template 
sample. 
For 1x reaction 
5x iScript  4µl 
iScript transcriptase 1µl 
Sterile water  x µl 
RNA template x µl 
 
Total volume  20µl 
 
3. Samples are transferred in Thermal Cycler: Dyad Disciple – machine on selected 
program. 
Program: 
Incubation +25 for 5 min 
Incubation +46 for 20min 
Incubation +95 for 1min 
Incubation +4  
Ending 
 
qPCR 
 
Prepare PCR mixes for MYB gene and for control gene G6PD  
(For 211 samples) 
Appendix 4 
   2 (2) 
 
  
MYB gene PCR mix 
- Probe buffer   1100 µl 
- Forward primer (10 µM)  44 µl 
- Reverse primer (10 µM) 44 µl 
- Probe  22 µl 
- Sterile water  880 µl 
 
G6PD gene PCR mix 
- Probe buffer   1100 µl 
- Primer mix   44 µl 
- Probe  44 µl 
- Sterile water  902 µl 
 
Pipette on 96-well plate 1µl of sample and 19µl of PCR mix to each well 
Program the Light Cycler 480 for 55 cycles (duration round 1,5 hours)  
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Charts 
 
Used amounts of RIPA buffer in cell lysis 
 Sample Confluence RIPA 
T25 flasks imatinib 
treatment after 24 
hours 
GIST 48 non-
treated 
60 % 200 µl 
GIST 48 imatinib 20 % 100 µl 
GIST 882 non-
treated 
100 % 400 µl 
GIST 882 imatinib 80 % 300 µl 
T25 flasks imatinib 
treatment after 48 
hours 
GIST 48 non-
treated 
80 % 200 µl 
GIST 48 imatinib 10 % 100 µl 
GIST 882 non-
treated 
100 % 400 µl 
GIST 882 imatinib 70 – 80 % 300 µl 
6-well plate siRNA 
transfection line 
882 after 48 hours 
(*not in the final re-
sults) 
GIST 882 negative 
control 
Not marked down 
in laboratory notes 
100 µl 
GIST 882 MYB 
siRNA 
Not marked down 
in laboratory notes 
100 µl 
GIST 882 KIT 
siRNA 
Not marked down 
in laboratory notes 
100 µl 
6-well plate siRNA 
transfection line 48 
after 48 hours 
(*not in the final re-
sults) 
 
GIST 48 negative 
control 
Not marked down 
in laboratory notes 
50 µl 
GIST 48 MYB 
siRNA 
Not marked down 
in laboratory notes 
50 µl 
GIST 48 KIT siRNA Not marked down 
in laboratory notes 
50 µl 
T25 flask siRNA 
transfection line 
882 after 48 hours 
GIST 882 negative 
control 
90 – 100 % 500 µl 
GIST 882 MYB 
siRNA 
80 – 90 % 500 µl 
GIST 882 KIT 
siRNA 
80 – 90 % 500 µl 
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T25 flask siRNA 
transfection line 48 
after 48 hours 
GIST 48 negative 
control 
90 – 100 % 500 µl 
GIST 48 MYB 
siRNA 
90 – 100 % 500 µl 
GIST 48 KIT siRNA 100 % 500 µl 
 
*6-well plate siRNA transfected cells were used at the beginning of the proses. Because 
of the difficulties of MYB antibody cell lysates ran out, new siRNA transfected cells were 
cultured in T25 flasks to get more lysate for western blotting.  
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Protein BCA absorbance measurements for western blotting  
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RNA purity and yield 
Sample of cell line 882 Yield of RNA ng/µl Purity of RNA 260/280 nm 
Validation control 1 14,7 1.92 
Validation control 2 12,7 1.84 
Validation control 3 10,3 2.05 
Non-treated cells 1 7,30 2.04 
Non-treated cells 2 7,90 1.97 
Non-treated cells 3 15,7 2.05 
Imatinib treated cells 1 4,40 1.53 
Imatinib treated cells 2 5,60 1.72 
Imatinib treated cells 3 4,70 1.62 
siRNA control 1 9,00 1.95 
siRNA control 2 8,00 1.99 
siRNA control 3 9,20 2.08 
MYB siRNA transfected 
cells 1 
5,20 2.12 
MYB siRNA transfected 
cells 2 
2,50 1.55 
MYB siRNA transfected 
cells 3 
4,90 1.85 
 
Sample of cell line 48 Yield of RNA ng/µl Purity of RNA 260/280 nm 
Validation control 1 16,4 1.94 
Validation control 2 23,3 1.94 
Validation control 3 20,7 2.05 
Non-treated cells 1 18,3 2.00 
Non-treated cells 2 19,3 2.01 
Non-treated cells 3 13,8 1.92 
Imatinib treated cells 1 4,01 2.29 
Imatinib treated cells 2 5,00 1.70 
Imatinib treated cells 3 4,70 1.91 
siRNA control 1 19,1 1.97 
siRNA control 2 25,3 1.95 
siRNA control 3 17,7 2.01 
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MYB siRNA transfected 
cells 1 
20,8 1.88 
MYB siRNA transfected 
cells 2 
20,3 2.08 
MYB siRNA transfected 
cells 3 
21,4 1.93 
 
Control sample Yield of RNA ng/µl Purity of RNA 260/280 nm 
MDA-MB-361 1893,7 2.12 
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96-well plate designs in qPCR 
 
Date: 25.5.2016  Plate: 1 
MYB gene          Control gene G6PD 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 882 
IM ctrl 
1 
882 
IM ctrl 
1 
882 
IM ctrl 
1 
882 
MYB 
siRNA 
1 
882 
MYB 
siRNA 
1 
882 
MYB 
siRNA 
1 
882 
IM ctrl 
1 
882 
IM ctrl 
1 
882 
IM ctrl 
1 
882 
MYB 
siRNA 
1 
882 
MYB 
siRNA 
1 
882 
MYB 
siRNA 
1 
B 882 
IM ctrl 
2 
882 
IM ctrl 
2 
882 
IM ctrl 
2 
882 
MYB 
siRNA 
2 
882 
MYB 
siRNA 
2 
882 
MYB 
siRNA 
2 
882 
IM ctrl 
2 
882 
IM ctrl 
2 
882 
IM ctrl 
2 
882 
MYB 
siRNA 
2 
882 
MYB 
siRNA 
2 
882 
MYB 
siRNA 
2 
C 882 
IM 1 
882 
IM 1 
882 
IM 1 
882 
MYB 
siRNA 
3 
882 
MYB 
siRNA 
3 
882 
MYB 
siRNA 
3 
882 
IM 1 
882 
IM 1 
882 
IM 1 
882 
MYB 
siRNA 
3 
882 
MYB 
siRNA 
3 
882 
MYB 
siRNA 
3 
D 882 
IM 2 
 
882 
IM 2 
882 
IM 2 
48 IM 
1 
48 IM 
1 
48 IM 
1 
882 
IM 2 
 
882 
IM 2 
882 
IM 2 
48 IM 
1 
48 IM 
1 
48 IM 
1 
E 882 
IM 3 
 
882 
IM 3 
882 
IM 3 
48 IM 
2 
48 IM 
2 
48 IM 
2 
882 
IM 3 
 
882 
IM 3 
882 
IM 3 
48 IM 
2 
48 IM 
2 
48 IM 
2 
F 882 
siRNA 
ctrl 1 
882 
siRNA 
ctrl 1 
882 
siRNA 
ctrl 1 
48 IM 
3 
48 IM 
3 
48 IM 
3 
882 
siRNA 
ctrl 1 
882 
siRNA 
ctrl 1 
882 
siRNA 
ctrl 1 
48 IM 
3 
48 IM 
3 
48 IM 
3 
G 882 
siRNA 
ctrl 2 
882 
siRNA 
ctrl 2 
882 
siRNA 
ctrl 2 
MDA-
MB-
361 
MDA-
MB-
361 
MDA-
MB-
361 
882 
siRNA 
ctrl 2 
882 
siRNA 
ctrl 2 
882 
siRNA 
ctrl 2 
MDA-
MB-
361 
MDA-
MB-
361 
MDA-
MB-
361 
H 882 
siRNA 
ctrl 3 
882 
siRNA 
ctrl 3 
882 
siRNA 
ctrl 3 
H2O H2O H2O 882 
siRNA 
ctrl 3 
882 
siRNA 
ctrl 3 
882 
siRNA 
ctrl 3 
H2O H2O H2O 
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Date: 25.5.2016  Plate: 2 
MYB gene                    Control gene G6PD 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 882 
valida-
tion 
ctrl 1 
882 
valida-
tion 
ctrl 1 
882 
valida-
tion 
ctrl 1 
48 IM 
ctrl 2 
48 IM 
ctrl 2 
48 IM 
ctrl 2 
882 
valida-
tion 
ctrl 1 
882 
valida-
tion 
ctrl 1 
882 
valida-
tion 
ctrl 1 
48 IM 
ctrl 2 
48 IM 
ctrl 2 
48 IM 
ctrl 2 
B 882 
valida-
tion 
ctrl 2 
882 
valida-
tion 
ctrl 2 
882 
valida-
tion 
ctrl 2 
48 
siRNA 
ctrl 1 
48 
siRNA 
ctrl 1 
48 
siRNA 
ctrl 1 
882 
valida-
tion 
ctrl 2 
882 
valida-
tion 
ctrl 2 
882 
valida-
tion 
ctrl 2 
48 
siRNA 
ctrl 1 
48 
siRNA 
ctrl 1 
48 
siRNA 
ctrl 1 
C 882 
valida-
tion 
ctrl 3 
882 
valida-
tion 
ctrl 3 
882 
valida-
tion 
ctrl 3 
48 
siRNA 
ctrl 2 
48 
siRNA 
ctrl 2 
48 
siRNA 
ctrl 2 
882 
valida-
tion 
ctrl 3 
882 
valida-
tion 
ctrl 3 
882 
valida-
tion 
ctrl 3 
48 
siRNA 
ctrl 2 
48 
siRNA 
ctrl 2 
48 
siRNA 
ctrl 2 
D 882 IM 
ctrl 3 
 
882 IM 
ctrl 3 
 
882 IM 
ctrl 3 
 
48 
siRNA 
ctrl 3 
48 
siRNA 
ctrl 3 
48 
siRNA 
ctrl 3 
882 IM 
ctrl 3 
 
882 IM 
ctrl 3 
 
882 IM 
ctrl 3 
 
48 
siRNA 
ctrl 3 
48 
siRNA 
ctrl 3 
48 
siRNA 
ctrl 3 
E 48 val-
idation 
ctrl 1 
48 val-
idation 
ctrl 1 
48 val-
idation 
ctrl 1 
48 
MYB 
siRNA 
1 
48 
MYB 
siRNA 
1 
48 
MYB 
siRNA 
1 
48 val-
idation 
ctrl 1 
48 val-
idation 
ctrl 1 
48 val-
idation 
ctrl 1 
48 
MYB 
siRNA 
1 
48 
MYB 
siRNA 
1 
48 
MYB 
siRNA 
1 
F 48 val-
idation 
ctrl 2 
48 val-
idation 
ctrl 2 
48 val-
idation 
ctrl 2 
48 
MYB 
siRNA 
2 
48 
MYB 
siRNA 
2 
48 
MYB 
siRNA 
2 
48 val-
idation 
ctrl 2 
48 val-
idation 
ctrl 2 
48 val-
idation 
ctrl 2 
48 
MYB 
siRNA 
2 
48 
MYB 
siRNA 
2 
48 
MYB 
siRNA 
2 
G 48 val-
idation 
ctrl 3 
48 val-
idation 
ctrl 3 
48 val-
idation 
ctrl 3 
MDA-
MB-
361 
MDA-
MB-
361 
MDA-
MB-
361 
48 val-
idation 
ctrl 3 
48 val-
idation 
ctrl 3 
48 val-
idation 
ctrl 3 
MDA-
MB-
361 
MDA-
MB-
361 
MDA-
MB-
361 
H 48 IM 
ctrl 1 
 
48 IM 
ctrl 1 
48 IM 
ctrl 1 
H2O H2O H2O 48 IM 
ctrl 1 
48 IM 
ctrl 1 
48 IM 
ctrl 1 
H2O H2O H2O 
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Date: 25.5.2016  Plate: 3 
MYB gene   Control gene G6PD 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 48 
MYB 
siRNA 
3 
48 
MYB 
siRNA 
3 
48 
MYB 
siRNA 
3 
48 
MYB 
siRNA 
3 
48 
MYB 
siRNA 
3 
48 
MYB 
siRNA 
3 
      
B 48 IM 
ctrl 3 
 
48 IM 
ctrl 3 
H2O 48 IM 
ctrl 3 
48 IM 
ctrl 3 
48 IM 
ctrl 3 
      
C MDA-
MB-
361 
MDA-
MB-
361 
H2O H2O H2O        
D             
E             
F             
G             
H             
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Relative expression of qPCR 
48 Validation control 1 0.5282 
48 Validation control 2 0.4337 
48 Validation control 3 0.3256 
48 Imatinib treated cells 1 0.3655 
48 Imatinib treated cells 2 0.2537 
48 Imatinib treated cells 3 0 
48 Non-treated cells 1 0.1979 
48 Non-treated cells 2 0.2190 
48 siRNA control 1 0.2608 
48 siRNA control 2 0.2324 
48 siRNA control 3 0.1808 
48 MYB siRNA transfected cells 1 0.2024 
48 MYB siRNA transfected cells 2 0.1742 
882 Validation control 1 0.4602 
882 Validation control 2 0.9377 
882 Validation control 3 0.5682 
882 Imatinib treated cells 1 6.77E-2 
882 Imatinib treated cells 2 0.2345 
882 Imatinib treated cells 3 0.3917 
882 Non-treated cells 1 0.7571 
882 Non-treated cells 2 1.171 
882 Non-treated cells 3 1.976 
882 siRNA control 2 1.001 
882 siRNA control 3 1.289 
882 MYB siRNA transfected cells 1 0.2591 
882 MYB siRNA transfected cells 3 0.4492 
882 MYB siRNA transfected cells 2 1.082 
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1 Introduction 
 
Meaning of cancer research is mainly to improve our own knowledge of cancer and that 
way find out ways to prevent the occurring of different cancers. Additionally, through 
research we can find ways to diagnose and treat cancer with improved ways. When we 
can find ways to fight back cancer, we can help to make people understand cancer bet-
ter. Through open and linked global connections, we can – as a society – accomplish 
great actions concerning the fight against cancer. (Cancer Research UK 2009 – 2014.) 
 
My part of cancer research comes in to the light through my thesis. Subject of my thesis 
is strongly linked to the research of GIST (Gastrointestinal stromal tumour) and its ori-
gins. In this particular research study, I am going to study the meaning of MYB gene 
expression in GIST cancer cell lines. Additionally, the basic function of protein production 
and ways to interfere this event, are examined during the research. Preliminary results 
of Dr. Sihto indicate that MYB might control transcription of the genes which are known 
to be associated with GIST tumorigenesis. The most common gene that causes GIST is 
so called KIT gene and about 85 – 95% of this kind of tumours arise from the mutation 
in the KIT gene. Basic purpose is to find ways to help preventing the formation of GIST 
cancer cells and understand more about how this particular tumour is shaped in the in-
testines. Furthermore, this study might help to find out more about genetics behind tu-
mour formation, especially concerning the role of MYB gene.  
 
By using cell culture, we can multiple the amount of GIST cancer cells that I am going to 
use in my study. The wanted knowledge of MYB gene expression can be detected by 
using western blotting. Western blotting reveals if these cells produce protein that is 
coded by the MYB gene. If these cells in fact do so, we can try reduce this protein pro-
duction by blocking the messenger RNA of MYB. To block mRNA we can utilize MYB 
specific Small interfering RNA. Additionally, the effect of imatinib in MYB gene expres-
sion and blocking the mRNA is added to this study. If the amount of protein decreases, 
we can assume that the amount of mRNA decreases in the same proportion. When the 
production of abnormal MYB controlled protein decreases, we might be able to see the 
effects of it in cell apoptosis or in cell proliferation in GIST cancer cells.  
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This study is conducted to the research group of Heikki Joensuu, University of Helsinki. 
Purpose of this study for the research team is to gain more knowledge of MYB gene-
function. They already have supporting evidence concerning my thesis and this evidence 
is the basic idea behind thesis. Already have been noticed in minor amounts that GIST 
cells produce the protein that is controlled by MYB gene. Protein production was discov-
ered through western blotting. Also early evidence has shown that the amount of mRNA 
decreases when e.g. siRNA is added to the cell culture. To reinforce this idea and to help 
deepen this evidence, I am going to repeat these analysis with more material during 
three weeks of practical laboratory analysis. My results will hopefully improve research 
team’s purpose of resolving the origins of GIST. 
 
My thesis consist of firstly this project plan, laboratory tests, analysing the results and 
then reporting them. In the final report I am going to demonstrate the materials, methods 
and analysing process accurately and finally discuss the matter and hopefully have a 
conclusion to my thesis. Information of this thesis is used to study more about MYB gene 
expression and in the further research of GIST. My priority is to figure out impact of MYB 
gene expression on GIST. If it indeed does have a considerable effect, we must ask 
ourselves how, why and under what conditions it effects GIST cells. 
 
Personally, I am aiming to increase my knowledge of transcription factors, interference 
of cancer cells, protein formation and also increase knowledge of siRNAs and Imatinib 
medication. On the side, the methods like cell culture and western blotting will come 
hopefully clearer to me. Generally, working in a research team and learning new ways 
of working, are my goals during the practical part of my study. I am also aiming to bring 
forth profitable information to help successfully GIST research. This thesis might work 
as a good base for the future research of MYB gene expression’s meaning in the for-
mation of GIST. 
2 Background 
 
The most recognised ability of cancer cells is their way of sustaining chronical prolifera-
tion. Normally tissues control their cell production and are able to release growth-pro-
moting signals that can guide the cell’s growth and division cycle. This release and con-
trol help to maintain homeostasis of the cell number and normal structure and function 
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of the cell. Cancer cells disturb these signals and this way determinate their own desti-
nies. This chronic proliferation can be sustained in multiple ways: they can produce 
growth factor signals, they can send signals to stimulate normal tissues, and they canin-
crease the levels of receptor proteins (in the cancer cell surface) and become hyperre-
sponsive towards growth factors. (Hanahan – Weinberg 2011.) 
 
Normal cells also use negative-feedback to control their homeostatic balance. Damage 
in negative-feedback systems are able to enhance proliferative signalling e.g. in cancer 
cells. Increasing expression of oncogenes and their protein production signals, on the 
other hand, can effect directly on elevated cancer cell proliferation and in that way to 
tumour growth. Additionally, cancer cells have to come up with programs that negatively 
monitor cell proliferation. These actions are partially dependant on the cells disappeared 
action of tumour suppressor genes. Above all cancer cells need nutrients and oxygen 
and a way to lose metabolic wastes that angiogenesis provides in the form of tumour-
associated neovasculature. (Hanahan – Weinberg 2011.) 
 
2.1 GIST 
 
GIST is an abbreviation for gastrointestinal stromal tumour. GISTs are gastrointestinal 
mesenchymal tumours that embody CD117 (KIT) proto-oncogene. GIST tumours are 
just 1 to 3 % of all of the GI tumours, but it is the most common soft tissue sarcoma of 
the gastrointestines. It is believed that GIST tumours originate from precursor cells of 
interstitial cells of Cajal, which are in control of spontaneous abdominal peristaltic move-
ments. Usually (50 – 60%), the treatment of GIST, includes the removal of the tumour. 
Additionally, imatinib can be used in metastatic GISTs or in GISTs that have a high risk 
of regeneration. (Lääkärin käsikirja 2014; Sihto 2016.)  
 
2.1.1 GIST diagnosis 
 
Generally GISTs are caused by active mutations in the KIT or PDGFRA genes. These 
tumours are normally found in stomach (60 %), small intestine, jejunum and ileum (30 
%), duodenum (5 %), rectum (2–3 %) and from the colon (1–2 %). GISTs consist of a 
group of neoplasms with various morphology, behaviour and genetic features. On histo-
pathologic view, GISTs are epithelioid-, spindle-, or mixed-cell tumours. These tumours 
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can be categorised as malignant, borderline or benign depending on its size, invasion to 
nearby tissues and mitotic index. (Poveda et al. 2013.) 
 
The diagnosis of these tumours mostly relies on its histopathological features and on the 
immunohistochemical phenotype. Anoctamin-1 (ANO1/DOG1) is known marker for 
GISTs and is used in differential diagnosis of GIST. Moreover, determination of KIT and 
PDGFRA mutations, are strongly connected to GIST diagnostics. These mutations are 
helpful to confirm diagnose in uncertain cases. The mutations can also help determinate 
the response of imatinib in tumours. (Gong – Li – Zhao – Zhao – Zhang 2009; Sihto 
2016.) 
 
2.1.2 Previous knowledge of GIST  
 
Ostrowski et al. studied molecular characteristics of type three tyrosine kinase receptor 
that is connected with known GIST mutations in KIT and PDGFRA. Both mutations are 
thought to promote early oncogenic events in similar pathways. Purified RNA from the 
GISTs and sequencing of mRNA was used to clarify these KIT and PDGFRA mutations. 
Most of the tumours possessed either or both of these mutations. Gene expression al-
tered between two groups of GISTs at some levels e.g. considering angiogenesis. Their 
study found new molecular elements that might be involved in receptor-dependent GIST 
evolution and also backed up previously known information about GIST receptors. These 
molecular elements might be good therapeutic targets and markers of KIT mutation sta-
tus. (Ostrowski et al. 2009.) 
 
Although, GISTs are usually localised in the GI tract, Gong et al. in year 2009 released 
an article about a GIST tumour found from sacrum in China. This particular tumour 
showed positive for both CD117 and CD34 proteins. Additionally, tumour showed posi-
tive morphological aspects for being GIST tumour and tumour was found positive in PCR 
of the mutation in c-KIT gene in exon 11. These facts strengthened the realization of this 
tumour being in fact GIST. In this study also brought to surface the clonal origins of GIST. 
GIST is (as shown before) considered to be a mesenchymal tumour and in this study 
GIST was proven to be monoclonal. Furthermore, 15 separate tumour nodules ex-
pressed loss of similar X chromosomal inactivation mosaicism. (Gong et al. 2009.) 
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2.2 MYB gene 
 
MYB is a proto-oncogene that is located on chromosome 6q in human genome. Its main 
function is to encode a 72 kDa nuclear binding transcription factor. Transcription factor 
in question is identified to be a sequence-specific DNA-binding transcriptional regulator 
protein in human cells. In this factor there are three main functional areas; amino termi-
nus as a DNA binding domain, mid portion as a transcriptional trans-activating domain 
and also carboxyl terminus as a negative regulator. MYB is especially found in hemato-
poietic cells and MYB expression is particularly high in immature hematopoietic cells. 
Recently MYB has been found also from non-hematopoietic cells and from cancer cells 
involving lung, breast, colon carcinoma and melanoma. (Kim et al. 2008.) 
 
2.2.1 Function of MYB gene 
 
The family of MYB genes consist of three different types of MYB, which are named A, B 
and c-myb. All of these genes encode proteins that are involved in transcription. In my 
study I focus on the gene c-myb and that particular gene is called in this thesis the MYB 
gene. The transactivation of different MYBs varies highly on different cell types and in 
promoter contexts. This variability between different MYBs suggests that there are also 
dependence with MYBs and other cell type specific co-factors e.g. interaction with other 
transcription factors. Gene expression of these genes is noticed to be cell cycle-regu-
lated. If this expression is inhibited with anti-sense oligonucleotides, it may effect on cell-
cycle progression, cell differentiation and cell division. (Oh – Reddy 1999.) 
 
V-myb is a transforming homolog oncogene of MYB that is connected to avian myelo-
blastosis virus (AMV) and to avian leukaemia virus E26. These viruses are strongly con-
nected to leukaemias. The so called v-myb genes are able to transform haematopoietic 
cells in tissue cultures and causes leukaemias in animals. Because the MYB protein is 
known to be a DNA-binding transcription factor, its oncogenic activity might be linked to 
its capacity to monitor specific target genes that impact cell reproduction or tumorigene-
sis. (Kim et al. 2008; Quintana et al. 2011.) 
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2.2.2 Role of MYB in cancer 
 
In research study of West et al. MYB gene was examined in adenoid cystic carcinoma 
(AdCC). It was discovered that translocation t(6;9) (q22-23;p23-24) was connected to 
multiple cases of AdCC. Moreover, the fusion between transcription encoding MYB gene 
and NFIB transcription factor in 6/11 occasions of AdCC was discovered. At that time 
only a potential pathogenic translocation suggested it to be a useful diagnostic ad-
vantage for differentiation of AdCC. In the study of West et al. MYB translocation was 
searched by increased levels of MYB expression. MYB translocation was discovered 
from one-half of the AdCC cases (49 %), but from the other salivary gland tumours there 
were no MYB translocation to be found. All in all, 65 % AdCCs have an unusual MYB 
FISH pattern, which indicates MYB translocation. (West et al. 2011.) 
 
Hudson and Collins studied furthermore the linkage between MYB gene and adenoid 
cystic carcinoma. Their main focus was to identify more diagnostic means to identify 
salivary gland basaloid neoplasms. CD117 with morphological aspects from fine needle 
biopsy are the most common ways to identify AdCC. Also AdCC tumours have a DNA 
abnormalities t(6;9) (q22-23;p23-24) translocation, which can be used as a diagnostic 
marker of this tumour. This particular translocations contains MYB gene that encodes 
transcription factors and is therefore specific for AdCC in salivary gland neoplasms. 
(Hudson – Collins 2014.) 
 
In Hudson – Collins study there were ten samples that were diagnosed as AdCC by using 
FNA (Fine needle aspiration) samples. Of these FNA samples, 50 % (5 cases) showed 
MYB gene abnormalities. These FNA samples were also compared with the most com-
mon diagnose method ergo histopathological analyse. It was furthermore pointed out 
that t(6;9) translocation is discovered also in adenoid cystic carcinoma of the breast as 
well as in the salivary gland. This translocation in question might make fusions to new 
gene partners. This fusion might lead to loss of control of the MYB gene expression, 
which is likely to effect to the neoplastic process in AdCC. (Hudson – Collins 2014.) 
  
Quintana et al. studied the role of MYB gene in breast cancer and MYB connection to 
estrogen levels and estrogen response in breast cancer cells. Their idea was that ex-
pression of MYB gene is associated with the estrogen receptors (ERs) in breast tumours. 
The MYB gene reacts to the activation of ERs in certain known breast cancer cell lines 
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like MCF-7. MYB transcription factor (shown in this study) is thought to be connected in 
the regulation of many different gene expressions that are important in breast cancer 
evolution and progression. Thus, when MYB gene is activated and starts to produce 
transcription factor, other genes react to this transcription factor and start e.g. producing 
breast cells in an uncontrolled way. Linkage to ERs in breast cancer may also indicate 
that MYB transcription factor is regulated mainly by different protein to protein interac-
tions. These Interactions may help to guide MYB transcription factor to different targets 
in multiple tissues. (Quintana et al. 2011.) 
 
Generally, there is only little known about MYB in tumorigenesis in human cells. More 
studies and advanced techniques may be required to resolve the mysteries of MYB. 
More results may help to understand which kind of signals and regulators are important 
in the role of controlling the activity of MYB transcription factor. However, it is not yet 
clear does the MYB transcription factor regulate genes that are involved in tumour 
growth. (Quintana et al. 2011.) 
 
2.3 Imatinib and siRNA 
 
Imatinib is a drug that is used in drug therapy of chronic myeloid leukaemia (CML) – that 
is Philadelphia-chromosome positive –, GISTs and acute lymphoblastic leukaemia etc. 
Imatinib is a kinase inhibitor that works by blocking the function of kinases with abnormal 
enzymatic activity. Target proteins for imatinib are i.a. oncoprotein BCR-ABL (connected 
with CML), KIT and PDGFR. These targets can be in charge of giving cancer cells signals 
to multiply without control. Imatinib helps preventing the uncontrolled way of growth in 
cancer cells. (Imatinib (Glivek) 2015; Sihto 2016; Lee – Wang 2009.) 
 
SiRNA is a small interfering RNA which job is to interfere expression of protein coding 
genes. SiRNA is a synthetic duplex RNA designed to attach identical corresponding 
mRNA in sequence to undermine its function. When attached, siRNAs can block the 
protein production. SiRNAs can also knockdown gene expression by causing promoter 
genes methylation and chromatin condensation. Their ability to induce gene knockdown 
is limited to cells that are receptive to transfection of synthetic oligonucleotides. (Ross –
Carlson – Brock 2007; Dharmacon 2016.) 
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2.4 Information retrieval 
 
I have been searching information for this thesis throughout the process. Articles and 
facts will be increased during the practical and reporting stage of this process. Mainly my 
search is restricted to different data bases on the internet. Helsinki Metropolia University 
of Applied sciences has open access to the data bases that I have used in my information 
retrieval. If possible, I will be using data bases of University of Helsinki during my practi-
cal part in research group of Heikki Joensuu. Some retrieval will be executed in different 
libraries e.g. in the library of Metropolia and in the library of University of Helsinki.  
3 Materials and methods 
 
Cell lines for my study are provided by Jonathan Fletcher MD from United States of 
America. Cell lines for imatinib-sensitive GIST (GIST882) and GIST (GIST48) are as-
sured by sequencing GISTs using their already known mutations spots. GIST cell lines 
are separated from human GIST cancer cells. (Bauer – Duensing – Demetri – Fletcher 
2007; Sihto 2016.) 
 
Received results will be analysed by using SPSS statistical program and also by using 
Microsoft Excell program.  
 
3.1 Cell culture 
 
In cell culture, cells are grown in an optimal artificial environment. Cells are removed 
from an animal or humans and they can be removed from tissues directly. Before the 
cultivation, cells can be manipulated by enzymatic or mechanical means or they can be 
separated from a cell line that has already been established. The condition to grow cells 
vary depending on the cell type in use. The artificial environment to grow cells though 
contains primarily the following aspects: 
 
- A substrate that includes essential nutrients (e.g. amino acids and carbohydrates) 
- Growth factors 
- Gases (oxygen and carbon dioxide) 
- Hormones 
Appendix 6 
   11 (18) 
 
 
- Regulated environment (pH, osmotic pressure, temperature) 
 
(Thermo Fisher Scientific 2016.) 
 
To culture cells in laboratory environment, the laboratory must have certain aspects. La-
boratory is recommended to be dust free and have no through traffic that can have a 
harmful effect to the cells. Laminar flow hoods allow these aspects to be fulfilled. Laminar 
flow hoods provide also an aseptic area for working with tissues. The laboratory should 
also be separated from the preparation place, wash-up and sterilization places, while still 
being close to each other. (Freshney 2010:25, 37.) 
 
An artificial substrate is a base where cultured cells can grow as monolayers or as a 
suspension. That is why the substrate must allow cell adhesions, which allows cells to 
grow and spread throughout the surface. The most commonly used substrate materials 
are disposable plastic and glass. These materials can be pre-treated with e.g. nutrients 
that improve cell attachment and growth. (Freshney 2010: 89–90.) 
 
Growth factors in serum stimulate cell proliferation, especially those factors that are 
platelet-derived (PDGF – platelet-derived growth factor). PDGF is known to stimulate 
growth particularly in glia cells and also in fibroblasts. Other growth factors such as fibro-
blast growth factors and epidermal growth factors are to be considered in cell cultures. 
Many of these factors are available for buying as recombinant proteins. Hormones that 
have a mitogenic feature, like insulin, growth hormone and hydrocortisone, are used in 
cell cultures. Insulin improves the up taking of glucose and amino acids. Hydrocortisone 
for its part, can promote cell to cell attachments. (Freshney 2010: 111.) 
 
As for the controlled and stable environment of the cell culture, cell type specification 
define the used physical aspects. Commonly most cells are accustomed to grow well at 
pH 7.4. Carbon dioxide helps lowering the pH by dissolving into bicarbonates. Addition-
ally, oxygen is required to maintain the cell respiration. Although, it is important to stable 
the oxygen level to the stage where it helps respiration but does not release toxins to the 
culture. The variation in osmolality is widely tolerated among different cells, but recom-
mended osmolality in culture is between 260 mOsm/kg and 320 mOsm/kg. As for tem-
perature, it is recommended to resemble the original source of the cells (growing human 
cells temperature is optimal in 37 Celsius). (Freshney 2010: 99–106.) 
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In my study cell culture will be based on aseptic work methods. GIST cells are grown in 
suitable environment (RPMI base). In to the medium of cell culture, heat inactivated FBS 
and suitable antibiotics are added. Cells are to be maintained by dividing them and by 
changing the base on regular basis. To this cell growth environment, imatinib can be 
added and incubated few days to let it effect on the cells of the culture. Small interfering 
RNAs are transfected to the cells by using Lipofectamine 2000 reagent. After the trans-
fection, cells are left also for few days before any further tests can be performed that the 
gene or protein expression has time to fade. (Sihto 2016.) 
 
3.2 Western blotting 
 
Western blotting is a technique that is used to separate wanted proteins based on a mass 
of proteins. Technique is based on transferring proteins from the separating gel onto a 
supporting matrix. This blotting style allows for fast staining and for destaining protocols 
of the separation of proteins. In western blotting, protein samples are separated in a gel 
through gel electrophoresis and after that electroblotted onto a support matrix. Once this 
is done, proteins can be labelled with anything that is able to selectively bind into pep-
tides to identify the presence or absence of specific spots. This detection of proteins can 
be reached via an enzyme fit for use with a changing ways of colorimetric, chemilumi-
nescent or fluorescent substrates. (Walker – Rapley 2005: 43.) 
 
After the gel electrophoresis, protein transfer from the gel is accomplished by using an 
electric potential through the gel and the membrane (support matrix see above) – where 
proteins are transferred to – which are in contact with each other. The applied membrane 
can be nitrocellulose, nylon or polyvinylidene difluoride (PVDF) base. This membrane 
provides much more stable environment than the gel, making later manipulations con-
siderably easier. Electroblotting is the most common western blotting technique, but also 
techniques such as capillary blotting can be used. (Walker – Rapley 2005: 43–44.) 
 
Following transfer to the membrane, finding of target proteins is commonly accomplished 
by using specific antibodies (protein labelling see above). The implantation of these spe-
cific antibodies to their target proteins can be performed by using methods that are based 
on indirect or direct immunoassays. Immunoassay methods include the using of multiple 
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labels that are conjugated to an antibody. In direct method, the signal of these labels is 
noticed directly when the antibody attaches itself to the protein that is looked for. When 
in indirect immunoassay methods, the signal can be achieved by using enzymes that 
can act on particular substrates. (Walker – Rapley 2005: 46.) 
 
In my study I am going to use SDS-PAGE gel electrophoresis and the used gels are 
directly bought from the Citylab. Gels are made by the Biorad Company. The used sec-
ondary antibody is labelled with HRP (horseradish peroxidase) and the chemilumines-
cent reaction on membrane on each protein is accomplished by exploiting enzymatic 
reactions. The magnitude of the reaction is directly correlated to the amount of protein in 
the sample. This chemiluminescent reaction is identified by using x-ray film. (SIhto 2016.)  
 
3.3 Permissions and reliability 
 
For my study I do not require any ethical permissions etc., because materials are not 
from patients, no animal testing is included nor genetically modified organisms are in-
cluded in my study. Reliability of my study depends on my materials, manners of my 
working and also on my references. These parts are processed in my reports discussion 
part at the final stage of my thesis.  
 
3.4 Schedule 
 
Schedule, concerning my working, is divided into four major parts. First there was an 
introduction to this subject, now I am planning my project, at May I am going to proceed 
the practical part of my study and at autumn will be the final reporting and writing of my 
thesis. I have scheduled my meetings with my instructors and made a quite accurate 
timetable to find information and to write my report. My schedule is also shown in Table 
1.  
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Table 1. Schedule 
4 Publication and communication  
This thesis will be published November 2016 at Vanha Viertotie campus of Helsinki 
Metropolia University of Applied Sciences. Thesis will be also available for the research 
group of Heikki Joensuu for future research on this subject. Online this thesis will be 
published to Theseus database. If recommended or needed, this thesis could be pub-
lished also somewhere else. Throughout this project I will be mentored and instructed by 
Harri Sihto from University of Helsinki, Laboratory of Molecular Oncology and by Hannele 
Pihlaja instructor of my thesis in Helsinki Metropolia University of Applied Sciences. 
Communication will be performed through email correspond and with regular meetings 
with both of my instructors.  
5 Discussion 
 
There are still some unclear subjects and open questions to my thesis. These subjects 
and questions are for the time being presented in this chapter. 
 
Questions and unclear subjects of my thesis: 
- Will there be enough time to finish this project? 
2016 Meetings Infor-
mation re-
trieval 
Writing Execution Due days Seminar 
Introduc-
tion to the 
subject 
Harri: 4.2 
Hannele: 
16.2 
7.2 – 19.2 16.2 – 25.2  25.2 1.3. 
Project 
plan 
Hannele: 
22.3 
week 10 10.3 – 29.3  31.3 5.4 – 6.4 
Execution  April – May  May  
weeks 19 – 
21 
  
Reporting 
and Final 
work 
 June –  
August 
June – 
October 
 8.11 
24.11 
15.11 – 
16.11 
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- Will my goals and abilities meet satisfactorily? 
- Will my information base be enough to meet the required standards? 
- Will there be enough time to make maybe more research in my thesis? 
- The use of statistical programs to decode my results 
- Succeeding in my practical works 
o How will imatinib and SiRNA react to GIST cells? 
o Succeeding in cell culture and western blotting 
- Further studies concerning GIST and MYB linkage 
 
5.1 Risk analysis 
 
To analyse possible risks linked to my thesis, I have made a SWOT-analysis to 
knowledge these risks. My main strengths, concerning this project, are the motivation 
that drives me to do this thesis satisfyingly to myself, eagerness to learn new things and 
being interested on the subject of this thesis. Moreover, well planned schedule, wide 
amount of references and organizing will help me throughout this project. Main weak-
nesses might be the limited amount of time that I have, stress, totally new subject to work 
with and the amount of work I have and want to put to this project.  
 
On the other hand, I see this project as an opportunity work in research group, which is 
a quite different and looked for environment to work in. Additionally – to learn new meth-
ods, to learn about cancer and gene function and also to work with new people – are 
great opportunities to me concerning my future as biomedical laboratory scientist. With 
opportunities there comes also threats that need to be seen. There is a threat that I will 
not be able to succeed in my goals in the limited amount of time given. Furthermore, 
possible disagreements and difficulties in finding consensus with people involved, is a 
threat that needs to be prevented and seen beforehand. My SWOT-analysis is also 
shown in a table form in Table 2.  
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Table 2. SWOT-analysis 
Strengths 
- motivation 
- eagerness to learn 
- interesting subject 
- well planned schedule  
- wide amount of references 
- organizing skills 
Weaknesses 
- limited amount of time 
- stress 
- unknown subject before 
- amount of work 
Opportunities 
- working in a research group 
- learning new methods 
- learning about cancer and genes 
- working with new people 
Threats 
- not succeeding my goals 
- limited amount of time 
- possible disagreements and not 
finding consensus with instructors 
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